AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Shahnaz Sultan,1,* Osama Altayar,2,* Shazia M. Siddique,3 Perica Davitkov,4 Joseph D. Feuerstein,5 Joseph K. Lim,6 Yngve Falck-Ytter,4 and Hashem B. El-Serag,7 on behalf of the AGA Institute*

BACKGROUND & AIMS: Multiple gastrointestinal (GI) symptoms, including diarrhea, nausea/vomiting, and abdominal pain, as well as liver enzyme abnormalities, have been variably reported in patients with coronavirus disease 2019 (COVID-19). This document provides best practice statements and recommendations for consultative management based on a systematic review and meta-analysis of international data on GI and liver manifestations of COVID-19. METHODS: We performed a systematic literature search to identify published and unpublished studies using OVID Medline and preprint servers (medRxiv, LitCovid, and SSRN) up until April 5, 2020; major journal sites were monitored for US publications until April 19, 2020. We pooled the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. RESULTS: We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%–8.2%), nausea/vomiting 7.8% (95% CI, 7.1%–8.5%), and abdominal pain 2.7% (95% CI, 2.0%–3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%) and alanine transaminase 15.0% (95% CI, 13.6%–16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%–20.1%). Isolated GI symptoms were reported rarely. We also summarized the GI and liver adverse effects of the most commonly utilized medications for COVID-19. CONCLUSIONS: GI symptoms are associated with COVID-19 in <10% of patients. In studies outside of China, estimates are higher. Further studies are needed with standardized GI symptom questionnaires and liver function test checks on admission to better quantify and qualify the association of these symptoms with COVID-19. Based on findings from our meta-analysis, we provide several Best Practice Statements for the consultative management of COVID-19.

Keywords: COVID-19; Gastrointestinal and Liver Manifestations.

The coronavirus family has 4 common human coronaviruses (ie, 229E, NL63, OC43, and HKU1) associated with the common cold, and 3 strains that are associated with pneumonia, respiratory failure, and death, including SARS-CoV (severe acute respiratory syndrome coronavirus), MERS-CoV (Middle Eastern respiratory syndrome coronavirus), and SARS-CoV-2.1 The novel coronavirus, SARS-CoV-2, was first described in December 2019 in patients in Wuhan, China who developed severe pneumonia, and was named coronavirus disease 2019 (COVID-19) by the World Health Organization on February 11, 2020.2 COVID-19 is estimated to have resulted in 2,896,633 cases in 185 countries with 202,832 deaths as of April 25, 2020.3 COVID-19 was first reported in the United States on January 20, 2020 and accounted for a total number of 938,154 cases and 53,755 deaths as of April 25, 2020. In the United States,
an early analysis of the first 4226 cases from the Centers for Disease Control and Prevention as of March 16, 2020 revealed estimated rates of hospitalization of 20.7%–31.4%; intensive care unit admission of 4.9%–11.5%; and case fatality of 1.8%–3.4%. More recent data from a cohort of 5700 hospitalized patients with COVID-19 within a large health care system in New York City revealed common comorbidities, including hypertension (56.6%), obesity (41.7%), and diabetes (33.8%), and reported that 373 patients (14.2%) required treatment in the intensive care unit, and 320 patients (12.2%) received invasive mechanical ventilation, in whom the mortality rate was 88.1% (282 of 320). Angiotensin converting enzyme II, believed to be the target entry receptor for SARS-CoV-2, is abundantly expressed in gastric, duodenal, and rectal epithelia, thereby implicating angiotensin converting enzyme II as a vehicle for possible fecal–oral transmission. In addition, angiotensin converting enzyme II receptors can be expressed in hepatic cholangiocytes and hepatocytes, potentially permitting direct infection of hepatic cells.

Nongastrointestinal symptoms for COVID-19 include fever, cough, shortness of breath, chills, repeated shaking with chills, muscle pain, headache, sore throat, and new loss of taste or smell. Gastrointestinal (GI) symptoms, including anorexia, nausea, vomiting, abdominal pain, and/or diarrhea have been reported in patients with COVID-19. Additionally, abnormal liver enzymes are also observed. However, significant heterogeneity has been observed in the reporting of GI and liver symptoms across settings. The most commonly reported GI symptom in COVID-19 is diarrhea, which has been reported in 1%–36% of patients. An updated characterization of the GI and liver manifestations across global settings is needed to further inform clinical guidance in the management of patients with COVID-19.

Table 1. Summary of Best Practice Statements: Consultative Management of Coronavirus Disease 2019

| Statement no. | Statement |
|---------------|-----------|
| 1             | In outpatients with new-onset diarrhea, ascertain information about high-risk contact exposure; obtain a detailed history of symptoms associated with COVID-19, including fever, cough, shortness of breath, chills, muscle pain, headache, sore throat, or new loss of taste or smell; and obtain a thorough history for other GI symptoms, including nausea, vomiting, and abdominal pain. |
| 2             | In outpatients with new-onset GI symptoms (eg, nausea, vomiting, abdominal pain, and diarrhea), monitor for symptoms associated with COVID-19, as GI symptoms may precede COVID-related symptoms by a few days. In a high COVID-19 prevalence setting, COVID-19 testing should be considered. |
| 3             | In hospitalized patients with suspected or known COVID-19, obtain a thorough history of GI symptoms (ie, nausea, vomiting, abdominal pain, and diarrhea), including onset, characteristics, duration, and severity. |
| 4             | There is presently inadequate evidence to support stool testing for diagnosis or monitoring of COVID-19 as part of routine clinical practice. |
| 5             | In patients (outpatients or inpatients) with elevated LFTs in context of suspected or known COVID-19, evaluate for alternative etiologies. |
| 6             | In hospitalized patients with suspected or known COVID-19, obtain baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19. |
| 7             | In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related GI and hepatic adverse effects. |

Scope and Purpose

We seek to summarize international data on the GI and liver manifestations of COVID-19 infection and treatment. Additionally, this document provides evidence-based clinical guidance on clinical questions that gastroenterologists may be consulted for. This rapid review document was commissioned and approved by the AGA Institute Clinical Guidelines Committee, AGA Institute Clinical Practice Updates Committee, and the AGA Governing Board to provide timely, methodologically rigorous guidance on a topic of high clinical importance to the AGA members and the public. Table 1 provides a summary of the recommendations and best practice statements.

Panel Composition and Conflict of Interest Management

This rapid review and guideline was developed by gastroenterologists and guideline methodologists from the 2 AGA committees. The guideline panel worked collaboratively with the AGA Governing Board to develop the clinical questions, review the evidence profiles, and develop the recommendations. Panel members disclosed all potential conflicts of interest according to AGA Institute policy.

Target Audience

The target audience of this guideline includes gastroenterologists, advanced practice providers, nurses, and other health care professionals. Patients as well as policy-makers can benefit from these guidelines. These guidelines are not intended to impose a standard of care for individual institutions, health care systems, or countries. They provide the basis for rational informed decisions for clinicians, patients, and other health care professionals in the setting of a pandemic.
Methods

Information Sources and Literature Search

We conducted a systematic literature search to identify all published and unpublished studies that could be considered eligible for our review, with no restrictions on languages. In the setting of a pandemic with exponential increases in published and unpublished studies, our search strategy was multifaceted. To capture relevant published articles, we electronically searched OVID Medline from inception to March 23, 2020 using the Medical Subject Heading term developed for COVID-19. We then searched the following platforms on April 5, 2020 for additional published and unpublished studies: medRxiv, Lit-Covid,11 and SSRN. An additional unpublished article under peer review was obtained through personal communication. For studies from the United States, we continued to monitor major journals for additional publications until April 19, 2020.

Study Selection and Data Extraction

Independent screening of titles and abstracts was performed by independent reviewers (P.D., S.S., J.F.) to identify potential studies for inclusion. A second reviewer (O.A.) subsequently reviewed the full-text articles and identified articles for inclusion. Any disagreements about inclusion were resolved through discussion. We incorporated any studies (prospective or retrospective) that reported on patient characteristics and symptoms of interest. For studies published in Chinese, we used Google translate to assess for potential inclusion and for data extraction.

Due to concerns about inclusion of the same patients in different publications, we used a hierarchical model of data extraction to minimize double counting of patients across similar institutions with coinciding dates of study inclusion. We aimed to identify and include data from the largest possible cohort from each location or hospital.12 Data extraction was performed using a 2-step process. The initial data extraction focused on data elements for study and patient characteristics. Subsequently, we identified studies for full data extraction based on study location (unique hospitals) and total number of patients. Additionally, when a study from a specific hospital did not provide all of the necessary information for the diarrhea symptoms, the next largest study from the same hospital (when available) was selected for inclusion in our analysis.

Data extraction was performed using a standardized Microsoft Excel data extraction form. Data extraction was performed in pairs; one study author independently extracted data while a second reviewer checked for accuracy of the data extraction (S.S., O.A., S.M.S., P.D., J.D.F., J.K.L., Y.F.Y., H.B.E.). Because the reporting of the data in the primary studies was suboptimal, a third reviewer (O.A.) additionally verified the extracted data to confirm the numbers and to resolve any disagreements. Studies with discrepancies in the data were excluded.

The following data elements were extracted:

1. Study: author, year, location (hospital name, city, province or state), dates of inclusion, and date of last follow-up
2. Patient characteristics: number of patients, age (mean, median, interquartile interval or range), number of females, severity of illness, inclusion criteria (hospitalized or outpatients), GI comorbidities (pre-existing conditions, such as chronic liver disease, hepatitis, and inflammatory bowel disease)
3. Outcomes: diarrhea, nausea, vomiting, abdominal pain, and liver function test (LFT) abnormalities
4. Additional information: severity, characteristics, duration, timing (before or concurrent with respiratory symptoms), relationship with clinical outcomes (need for ventilator, survival, discharge, and continued hospitalization), and viral stool shedding.

Assessment of Risk of Bias

We assessed the risk of bias according to the following domains as suggested in the ROBINS-I tool for nonrandomized studies.13

1. Bias due to selection of participants in the study
2. Bias due to missing data
3. Bias in the measurement of outcomes
4. Bias in the selection of the reported result

We considered the domains for each study and then made a judgment of high or low risk of bias for the studies included in the meta-analysis.

Certainty of Evidence

Certainty of evidence was evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. The certainty of evidence was categorized into 4 levels ranging from very low to high. Within the GRADE framework, evidence from randomized controlled trials (RCTs) starts as high-certainty evidence and observational studies start out as low-certainty evidence, but can be rated down for the following reasons: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Additionally, evidence from well-conducted observational studies start as low-certainty evidence, but can be rated up for large effects or dose-response.14

Data Synthesis and Analysis

A meta-analysis of prevalence of GI and liver abnormalities was performed using meta 4.11-0 package in R software, version 3.6.3.15,16 The prevalence was expressed as a proportion and 95% confidence interval (CI). We used the fixed-effects model using the Freeman-Tukey double arc sine transformation method for proportions. This is the preferred method of transformation and avoids giving an undue larger weight to studies with very large or very small prevalence.17,18 The I² statistic was used to measure heterogeneity.19 To explore heterogeneity, we performed subgroup analyses based on the location (region) of the study and clinical settings (inpatient vs outpatient). To assess the robustness of our results, we performed sensitivity analyses by limiting the included studies to those that clearly reported the presence of symptoms at initial presentation.

Results

A total of 57 studies were ultimately selected for complete data extraction; 56 from our search and 1 additional manuscript (under review) was included to provide more data on a US cohort20-22 (see Supplementary Figure 1 for Preferred Reporting Items for Systematic Reviews and
Meta-Analyses flow diagram. Of the 57 selected studies, 47 reported on unique patients based on hospital name (with no duplication of cohorts from the same hospital). An additional 10 studies were identified with potentially overlapping cohorts based on hospital name, but these were included if they provided unique information about a specific symptom (eg, diarrhea at initial presentation when the larger cohort did not clearly state that it was at initial presentation). Based on our comprehensive selection process, we believe that the included 47 studies reported data on 10,890 unique COVID-19 patients. The majority of studies (70%) in our analysis were from China; these were selected from 118 reports published or prepublished from China (Supplementary Figure 2). The studies included mainly pediatric patients. Two studies reported on outpatients only, whereas the remaining 55 studies reported on hospitalized patients or a combination of outpatients and hospitalized patients. Based on our inclusion strategy: 55 studies (96%) provided information on any GI symptom and 32 studies (56%) reported any data on liver abnormalities. (96%) provided information on any GI symptom and 32 studies (56%) reported any data on liver abnormalities. The studies included mainly adults, although a few studies included a small proportion of pediatric patients. Two studies reported on outpatients only, whereas the remaining 55 studies reported on hospitalized patients or a combination of outpatients and hospitalized patients. Based on our inclusion strategy: 55 studies (96%) provided information on any GI symptom and 32 studies (56%) reported any data on liver abnormalities. Fewer studies, 21 (37%), provided information on underlying GI conditions. Table 2 provides a summary of the pooled prevalence estimates.

**Overall Certainty of Evidence**

The overall certainty in the body of evidence was low. Our confidence in the pooled estimates of prevalence was reduced because of concerns of risk of bias (ie, selection bias, detection bias, and attrition bias), heterogeneity of the tested patient populations (inconsistency), as well as issues of indirectness (the majority of studies included primarily symptomatic hospitalized patients instead of all patients with COVID-19). Additionally, most of the studies were retrospective cohort series and did not specify whether consecutive patients were included in the analysis. Other limitations included inconsistent assessment of symptoms and/or laboratory tests, missing data and/or inconsistent reporting of data, and insufficient follow-up of the patients. These factors may have contributed to the heterogeneity of findings across studies. The $I^2$ statistic ranged from 77% to 98% and was not completely explained by geographic location or by outpatient vs inpatient status.

**What are the Gastrointestinal Manifestations of COVID-19?**

**Diarrhea.** A total of 43 studies including 10,676 COVID-19 patients (confirmed by laboratory real-time reverse transcription polymerase chain reaction [RT-PCR] testing) were included in the overall analysis. The pooled prevalence of diarrhea symptoms across these studies was 7.7% (95% CI, 7.2%–8.2%). When analyzing by country (studies from China vs studies from other countries), the pooled prevalence of diarrhea in studies from countries other than China was much higher at 18.3% (95% CI, 16.6%–20.1%). This is in comparison to studies from China, where the prevalence was much lower at 5.8% (95% CI, 5.3%–6.4%) (Figure 1).

In hospitalized patients, across 39 studies including 8,521 patients, the pooled prevalence was slightly higher at 10.4% (95% CI, 9.4%–10.7%) compared with outpatients.20-23,26-28,31,33-35,38,41,42,44,45,47,48,50,55,56,60,62-65,67,70-74,76 In 3 studies including 1701 outpatients, the pooled prevalence was 4.0% (95% CI, 3.1%–5.1%).21,59,63 As part of the sensitivity analysis, we identified 35 studies including 9717 patients that described diarrhea, and explicitly reported that it was one of the initial presenting symptoms.20-23,26-28,31,33-35,38,41,42,44,45,47,48,50,55,56,60,62-65,67,70-74,76 The pooled prevalence in these studies was 7.9% (95% CI, 7.4%–8.6%). A total of 33 studies including 8070 patients reported on hospitalized COVID-19 patients presenting with diarrhea as one of the initial symptoms of COVID-19.20-23,26-28,31,33-35,38,41,42,44,45,47,48,50,55,56,60,62-65,67,70-73,76 The pooled prevalence was 9.3% (95% CI, 8.6%–9.9%) (Supplementary Figures 3–6).

**Description of diarrhea.** Only a handful of studies provided any details on the type and severity of diarrhea symptoms.55,60,74 In the study by Lin et al,55 23 of 95 patients (24%) reported having diarrhea (described as loose or watery stools, ranging from 2–10 bowel movements per day); however, only a small number of patients actually

### Table 2. Summary of the Pooled Prevalence Estimates of Gastrointestinal/Liver Manifestations

| GI and liver manifestations | All studies | Studies from China | Studies from countries other than China |
|----------------------------|-------------|--------------------|---------------------------------------|
|                            | % (95% CI)  | Patients/ studies, n | % (95% CI)  | Patients/ studies, n | % (95% CI)  | Patients/ studies, n |
| Diarrhea in all patients$^a$ | 7.7 (7.2 to 8.2) | 43/10,676 | 5.8 (5.3 to 6.4) | 32/8612 | 18.3 (16.6 to 20.1) | 11/2064 |
| Nausea/vomiting in all patients$^a$ | 7.8 (7.1 to 8.5) | 26/6955 | 5.2 (4.4 to 5.9) | 19/4054 | 14.9 (13.3 to –16.6) | 7/1901 |
| Abdominal pain in all patients$^a$ | 3.6 (3.0 to 4.3) | 15/4031 | 2.7 (2.0 to 3.4) | 10/2447 | 5.3 (4.2 to 6.6) | 5/1584 |
| Patients with elevated AST | 15.0 (13.6 to 16.5) | 16/2514 | 14.9 (13.5 to 16.4) | 14/2398 | 20.0 (12.8 to 28.1) | 2/116 |
| Patients with elevated ALT | 15.0 (13.6 to 16.4) | 17/2711 | 14.9 (13.5 to 16.3) | 15/2595 | 19.0 (12.0 to 27.1) | 2/116 |
| Patients with elevated total bilirubin | 16.7 (15.0 to 18.5) | 10/1841 | 16.7 (15.0 to 18.5) | 10/1841 | — | — |

$^a$Regardless of hospitalization and timing of symptoms.
had diarrhea on admission (5.2%). Most patients developed diarrhea during the hospitalization, which may have been attributable to other treatments or medications. In the study by Jin et al.\(^60\) of 651 hospitalized patients, 8.6% of patients had diarrhea on admission before receiving any treatments. The diarrhea symptoms were described as more than 3 loose stools per day. Stool cultures were negative (including \textit{Clostridium difficile}) in all patients. There was no mention of fecal leukocytes. Median duration of symptoms was 4 days (range, 1–9 days) and most patients had self-limited diarrheal symptoms.\(^60\) One additional study on 175 hospitalized patients reported that 19.4% of patients had diarrhea, with an average of 6 episodes per day, with symptom duration ranging from 1 to 4 days.\(^74\)

### Diarrhea as the only presenting symptom in the absence of upper respiratory symptoms.

In the 43 studies that informed our analysis on the prevalence of diarrhea, we extracted information on whether diarrhea was reported as the only presenting symptom.\(^50,60\) In only 2 studies, there was explicit reporting of diarrhea in the absence of upper respiratory infection symptoms. In a study by Luo et al.\(^50\) of 1141 patients, 183 patients (16%) presented with GI symptoms only in the absence of respiratory symptoms. Of these patients, loss of appetite (15.8%) and nausea or vomiting (11.7%) were the most common symptoms, but diarrhea was reported in 6.0% and abdominal pain in 3.9% of patients. Notably, the majority of patients (96%) had lung infiltrates on chest computed tomography. In the study by Jin et al.\(^60\) of 651 hospitalized patients, 21 patients (3.2%) presented with GI symptoms only (and no respiratory symptoms of coughing or sputum production).\(^60\) GI symptoms were defined as at least 1 of the following symptoms: nausea, vomiting, and diarrhea. Conversely, in the US study of 116 patients with COVID-19, Cholankeril et al.\(^70\) reported that 31.9% of patients had GI symptoms on admission (median duration, 1 day); diarrhea was reported in 10.3% (12 of 116), nausea and/or vomiting in 10.3% (12 of 116), and abdominal pain in 8.8% (10 of 116). The authors explicitly reported that none of the 116 patients had isolated GI symptoms as the only manifestation of COVID-19.

### Diarrhea as the initial presenting symptom preceding other COVID-19 symptoms.

Of the studies included in our review, based on our selection framework, we identified only 1 study that reported on timing of diarrhea in relation to other COVID-19–related symptoms. In a study by Ai et al.\(^76\) of 102 hospitalized patients, 15 patients reported diarrhea symptoms on hospital admission, and diarrhea was
the first symptom in 2 patients. In a study by Wang et al. of 138 consecutive hospitalized patients, not included in our pooled analysis, a total of 14 patients presented with diarrhea and nausea 1–2 days before the development of fever and dyspnea.

**Nausea/vomiting.** A total of 26 studies including 5955 patients with COVID-19 (confirmed by laboratory RT-PCR testing), were included in the overall analysis for nausea and/or vomiting.20,22,23,25,27,29,34,37,41,45–47,50,51,54,55,59,63,65,67,68,70 The pooled prevalence of nausea/vomiting was 7.8% (95% CI, 7.1%–8.5%). A subgroup analysis of 1901 patients from 7 studies (including patients from Germany, Singapore, United States, Australia, and The Netherlands) demonstrated a higher pooled prevalence of 14.9% (95% CI, 13.3%–16.6%).37,46,47,59,63,68,70 This is in comparison to the prevalence of symptoms in studies from China, which was 5.2% (95% CI, 4.4%–5.9%) (Figure 2 and Supplementary Figure 7).

**Abdominal pain.** A total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21,23,27,37,50,54,55,63,69–73,76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6%) compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.27,39,59,63,65,76 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).

**Stool shedding.** Our study selection criteria prioritized including studies with diarrhea as a GI manifestation and avoiding overlap in populations and, therefore, did not include a comprehensive set of studies reporting on stool shedding. A recently published systematic review by Cheung et al.10 found a 48.1% (95% CI, 38.3%–59.7%) pooled prevalence of stool samples positive for virus RNA in 12 studies. Stool RNA was positive in 70.3% of samples taken from patients after respiratory specimens were no longer positive for the virus.

From the 57 studies included in our analysis, 4 studies reported on presence of viral RNA in stool.24,32,57,68 Of these, 3 studies were published after the systematic review by Cheung et al.10 First, Dreher et al.68 conducted a retrospective cohort study in Germany, stratifying patients by presence of acute respiratory distress syndrome. In this study, 8 of 50 patients had diarrhea, and stool PCR was positive in 15 of 50 patients. In a US study by Kujawski et al.,57 stool PCR was positive in 7 of 10 patients. Finally, in a case series from Germany by Wolfel et al.,32 the authors not only examined stool RNA but also tried to isolate virus from laboratory specimens. In this study, 2 of 9 patients had diarrhea as an initial symptom and stool PCR remained positive for up to 11 days, but notably, the authors were unable to isolate infectious virus, despite a high stool viral RNA load, even though the virus was successfully isolated from respiratory specimens. The authors concluded that stool is not a primary source of spread of infection.12 Conversely, in a letter published by Wang et al.,27 the authors collected 1070 specimens from 205 hospitalized patients with COVID-19 and 44 of 153 stool specimens (29%)

### Table

| Location = China | Location = Out of China | Percentage | 95% CI Weight |
|------------------|-------------------------|------------|---------------|
| Study            | Location                | N/V Total  |               |
| HuSh, 2020       | Hubei                   | 0          | 545           |
| LiU, 2020        | Hubei                   | 0          | 153           |
| Qi, 2020         | ChongQing               | 0          | 627           |
| Lu, 2020         | Shanghai                | 0          | 265           |
| Wei, 2020        | Hubei                   | 1          | 200           |
| Chen, 2020       | AnHui                   | 0          | 9             |
| Fu, 2020         | Sichuan                 | 1          | 52            |
| Zhou, 2020       | Hubei                   | 7          | 191           |
| Yan, 2020        | Hainan                  | 9          | 168           |
| Chen, 2020       | Hunan                   | 17         | 291           |
| Xu, 2020         | Guangdong               | 5          | 90            |
| Fan, 2020        | Liaoning                | 4          | 55            |
| Zhao, 2020       | Beijing                 | 6          | 77            |
| Yao, 2020        | Shandong                | 3          | 40            |
| Chen, 2020       | Hubei                   | 2          | 274           |
| Ai, 2020         | Hubei                   | 9          | 102           |
| Luo, 2020        | Hunan                   | 13         | 1141          |
| Zhang, 2020      | Hubei                   | 2          | 139           |
| Lin, 2020        | Guangdong               | 17         | 95            |
| Fixed effect model |                         | 277        | 4905          |

**Figure 2.** Forest plot of the prevalence of nausea/vomiting in all patients.
were positive for viral RNA. Four specimens with high copy numbers were cultured and electron microscopy was performed to detect live virus, which was observed in the stool from 2 patients who did not have diarrhea. The authors concluded that although this does not confer infectivity, it raised the possibility of fecal–oral transmission. The small sample size of the reports that assessed the presence of live virus in stool combined with the conflicting findings limit our certainty in the evidence and thus the question of fecal–oral transmission remains unsettled.

What Are the Liver Manifestations of COVID-19?

Based on our inclusion strategy, 34 of the 57 studies (60%) reported any data on liver abnormalities. The majority of the studies that reported data on LFTs only reported continuous summary statistics (median and interquartile range) without reporting the number of patients with abnormal levels. Abnormal aspartate transaminase (AST), defined as any value above the upper limit of normal (ULN), was reported in 15.0% (95% CI, 13.6%–16.5%) of patients across 16 studies, including 2514 COVID-19 patients. Abnormal alanine transaminase (ALT), defined as any value above the ULN, was reported in 15.0% (95% CI, 13.6%–16.4%) of patients across 17 studies including 2711 COVID-19 patients. Abnormal bilirubin, defined as any value above the ULN, was reported in 16.7% (95% CI, 15.0%–18.5%) of patients across 10 studies including 1841 COVID-19 patients. All patients had confirmed COVID-19 by laboratory RT-PCR testing.

The study by Cholankeril et al reported that 26 of 65 patients (40%) had abnormal liver enzymes and 22 of them had normal baseline liver enzymes. None of the remaining studies provided any information regarding the status of LFTs before the infection. One study by Fu et al reported summary statistics (median and interquartile range) of LFTs for 23 patients on admission and discharge with no clinically important changes. However, they did not provide the number of patients who presented with normal or abnormal LFTs and how many of them improved or worsened. None of the included studies reported the workup of LFTs in the settings of COVID-19 or assessed whether they were related to alternative etiologies, especially medications. Thirteen studies reported on the association between the presence of liver injury at presentation and severity of disease or outcomes. Most of them reported the results of univariate analyses. The study by Hajifa-thalian et al reported the results of multivariate analyses that included multiple variables and showed liver injury at presentation was associated with high risk for admission, as well as higher risk of intensive care unit admission and/or death as a composite outcome (Supplementary Figures 9–11).

Rationale for Best Practice Statements

1. In outpatients with new-onset diarrhea, ascertain information about high-risk contact exposure; obtain a detailed history of symptoms associated with COVID-19, including fever, cough, shortness of breath, chills, muscle pain, headache, sore throat, or new loss of taste or smell; and obtain a thorough history for other GI symptoms, including nausea, vomiting, and abdominal pain.

2. In outpatients with new-onset GI symptoms (eg, nausea, vomiting, abdominal pain, and diarrhea), monitor for symptoms associated with COVID-19, as GI symptoms may precede COVID-related symptoms by a few days. In a high COVID-19 prevalence setting, COVID-19 testing should be considered.

3. In hospitalized patients with suspected or known COVID-19, obtain a thorough history of GI symptoms (ie, nausea, vomiting, abdominal pain, and diarrhea), including onset, characteristics, duration, and severity.

The overall prevalence of GI symptoms in context of COVID-19, including nausea, vomiting, abdominal pain, and diarrhea, is lower than estimated previously. It is
important to note that the majority of studies were focused on hospitalized patients with COVID-19, and the prevalence of diarrhea in patients with mild symptoms who were not hospitalized is not known. Therefore, the reported prevalence rates may represent either an overestimate or underestimate. Information about the frequency and severity of diarrhea symptoms was inadequately reported in the majority of studies.

Based on our analysis, among hospitalized patients, the prevalence of diarrhea as the only presenting symptom in the absence of other COVID-related symptoms was very low. The majority of patients with diarrhea, nausea, or vomiting also presented with accompanying symptoms typically associated with COVID-19. In a handful of studies, diarrhea and nausea preceded the development of other COVID-related symptoms. In a US case-control study of 278 COVID-19 patients, patients with GI symptoms were more likely to have illness duration of 1 week or longer (33%) compared to patients without GI symptoms (22%). This may have been attributable to a delay in testing.47 Therefore, in high prevalence settings, among patients presenting with new-onset diarrhea, monitoring for the development of COVID-19 symptoms and considering referring patients for COVID-testing is reasonable, especially if testing capacity is not limited.

The Centers for Disease Control and Prevention has recently expanded the criteria for COVID-19 testing to include presence of olfactory and gustatory symptoms as triggers for testing, as these symptoms have been demonstrated to occur in up to 80% of patients.79 As of April 19, 2020, diarrhea as an initial preceding symptom of COVID-19 has not been included on the Centers for Disease Control and Prevention symptom checklist.

To more accurately inform our understanding of the true prevalence of diarrhea, nausea, and vomiting as a manifestation of COVID-19, it is critical to systematically collect information about onset of diarrhea; duration of symptoms; and documentation of whether and how long symptoms of diarrhea, nausea, and vomiting precede upper respiratory infection symptoms. Therefore, we advise health care professionals and researchers to obtain a thorough review of systems, systematically inquire about respiratory and GI symptoms, and ascertain information about exposure.

4. There is presently inadequate evidence to support stool testing for diagnosis or monitoring of COVID-19 as part of routine clinical practice.

While stool shedding has been reported in a prior meta-analysis in 48.1% of specimens, 2 small case series showed conflicting findings about the presence of living virus in stool.10,25,78 Therefore, stool infectivity and transmission have not been confirmed. Further studies are needed to determine whether isolated virus from stool specimens confers infectivity and determine the role of stool testing is in patients with COVID-19.

5. In patients (outpatients or inpatients) with elevated LFTs in context of suspected or known COVID-19, evaluate for alternative etiologies.

6. In hospitalized patients with suspected or known COVID-19, obtain baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19.

7. In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related GI and hepatic adverse effects.

Abnormal LFTs were reported in approximately 15% of patients across the pooled studies, but with variable reporting of mean or median values for the whole sample of patients. While the studies used in this analysis helped us to better understand the prevalence of abnormal LFTs among hospitalized patients, LFT abnormalities were not consistently reported across studies. Also, many of the studies in this analysis did not report on how many patients had underlying liver disease and whether these patients were at an elevated risk of having increased LFTs in the setting of COVID-19 infection. Furthermore, diagnostic evaluation of abnormal LFTs on admission was not performed routinely, such as testing for viral hepatitis or other etiologies. The available studies suggest that abnormal LFTs are more commonly attributable to secondary effects (eg, systemic inflammatory response syndrome, cytokine storm, ischemic hepatitis/shock, sepsis, and drug hepatotoxicity) than primary virus-mediated hepatocellular injury.2,9,60 However, liver histopathology from patients with COVID-19 have revealed mild lobular and portal inflammation and microvesicular steatosis suggestive of either virally mediated or drug-induced liver injury.41 In addition, some studies have revealed that abnormal LFTs at hospital admission may be associated with a higher risk for severe COVID-19 (odds ratio, 2.73; 95% CI, 1.19–6.3). Therefore, we advise checking baseline LFTs in all patients on admission and monitoring of LFTs throughout the hospitalization, particularly in patients undergoing drug therapy for COVID-19 associated with potential hepatotoxicity. We additionally advise that all patients with abnormal LFTs undergo an evaluation to investigate non–COVID-19 causes of liver disease.

What Are Common Gastrointestinal/Liver Adverse Effects of COVID-19 Treatments?

There are currently no US Food and Drug Administration–approved routine treatments for COVID-19. The FDA has issued an emergency use authorization for 3 therapies: chloroquine or hydroxychloroquine, remdesivir, and convalescent plasma.82 In China and Japan, favipiravir has been approved for the treatment of COVID-19. Numerous medications are under investigation; the World Health Organization is spearheading a multinational, multicenter trial for the 5 treatments highlighted below.83 We aim to provide a summary of the GI and liver adverse effects of the most commonly utilized medications for COVID-19 at this time, irrespective of their efficacy. Medication GI-related adverse events are summarized in Supplementary Tables 1 and 2 (direct evidence sources and indirect evidence sources).
Antimalarial Medications

Although efficacy and subsequent optimal dosing in COVID-19 is still under investigation, both chloroquine and hydroxychloroquine are currently FDA-approved in the United States for other indications (ie, malaria and systemic lupus erythematosus) and now have an emergency use authorization for use in COVID-19.

Chloroquine and hydroxychloroquine. Both chloroquines have reported infrequent GI adverse effects (ie, nausea, vomiting, abdominal pain, and diarrhea).84,85 The National Institute of Health LiverTox resource rates both drugs with a likelihood score of D (possible rare cause of clinically apparent liver injury).86 Chloroquine is rarely linked to aminotransferase elevations or clinically apparent liver injury. In patients with acute intermittent porphyria or porphyria cutanea tarda, it can trigger a hypersensitivity attack with fever and serum aminotransferase elevations, sometimes resulting in jaundice. This is seen less commonly with hydroxychloroquine. Such reactions are thought to be hypersensitivity reactions and there is no known cross-reactivity in liver injury between hydroxychloroquine and chloroquine. Hydroxychloroquine is known to concentrate in the liver, thus patients with hepatitis or other hepatic diseases, or patients taking other known hepatotoxic drugs, should exercise caution. In addition, cardiac conduction defects leading to clinically relevant arrhythmias are an important adverse effect of these medications.

Antiviral Medications

Remdesivir. Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably GI and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases.

Lopinavir/ritonavir. The combination lopinavir/ritonavir is FDA-approved for the treatment of human immunodeficiency virus (HIV). More recently, it was utilized to treat MERS and SARS. There is 1 trial by Cao et al89 that randomized 199 hospitalized patients with severe COVID-19 to receive treatment to lopinavir/ritonavir (n = 99) or placebo (n = 100) for 14 days. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence among those receiving higher doses. Other GI adverse events in HIV are similar to Cao et al’s RCT, with nausea in 5%–15% and vomiting in 5%–10% of patients90 (Table 3).

The Cao et al90 RCT did not show a significant increase in hepatotoxicity in the treatment compared to the control group. However, in patients with HIV, there is a well-documented known risk of hepatotoxicity, with liver injury severity ranging from mild enzyme elevations to acute liver failure.91 Moderate-to-severe elevations in serum aminotransfereases, defined as more than 5 times the ULN, are found in 3%–10%.67 Rates may be higher in patients with concurrent HIV and hepatitis C virus co-infection. In some cases, mild asymptomatic elevations are self-limited and can resolve with continuation of the medication, but re-challenging the medication can also lead to recurrence and, therefore, should be avoided when possible. Acute liver failure, although reported, is rare. Ritonavir has potent effects on cytochrome P450 and therefore affects drug levels of a large number of medications typically given in GI practices.

Favipiravir. There are 2 published studies on favipiravir in COVID-19. The first is an open-label RCT for favipiravir vs arbidol conducted in Wuhan, China by Chen et al.92 This study reported digestive tract reactions, including nausea, “anti-acid,” or flatulence in 13.79% (16 of 116) of the favipiravir group. Hepatotoxicity characterized by any elevation in AST or ALT was reported in 7.76% (9 of 116). The second is an open-label control study of favipiravir or lopinavir/ritonavir, both used in conjunction with interferon alfa, for COVID-19 by Cai et al,93 which reported diarrhea in 5.7% (2 of 35) and liver injury in 2.9% (1 of 35) (Supplementary Tables 2 and 3).

Limitations of the Evidence on Gastrointestinal and Liver Manifestations in Patients With COVID-19 Infection

The individual studies in our analysis were at high risk of bias. The majority of studies reported on cohorts of patients based on inclusion dates and did not specify whether these were consecutive patients. There was an inconsistent assessment of symptoms and/or laboratory tests with missing data, and none of the studies reported whether patients were systematically evaluated for GI symptoms on admission. Most studies did not report on the duration of the GI symptoms preceding the presentation. When GI symptoms were reported, it was difficult to discern whether these were isolated symptoms or whether patients also had concurrent typical COVID-19 symptoms (eg, fever, cough or shortness of breath). LFTs were mostly reported as the mean/median value of the entire cohort and without cutoff values for the institution. Many of the studies did not report on underlying chronic GI or liver diseases. There was a lot of heterogeneity in our pooled estimates that could not be explained by our subgroup analysis based on geographic location. Lastly, the data on prognosis were especially difficult to analyze due to insufficient follow-up of the patients (the majority of the patients were still hospitalized at
the time of publication). Finally, there was no stratification of GI-related symptoms and severity of COVID-19 or patient important outcomes, such as need for intensive care unit or survival.

There may be additional limitations of our findings based on our analysis. Due to concerns about overlapping cohorts, we used a hierarchical framework to identify unique cohorts based on the number of patients and the hospitals to analyze the prevalence of GI and liver symptoms. It is possible that we excluded relevant studies that provided more granularity regarding the GI and liver manifestations, or had more systematic assessment of outcomes. As a result, this may have led to an over- or underestimation of the pooled effect estimates. However, we have high confidence that we were able to eliminate the counting of some patients in more than 1 report by using our selection framework, unless they were transferred from one hospital to another. An important strength of this study is the appropriate statistical analysis used to pool proportions. We also reviewed gray literature from pre-publication repositories, which allowed us to include a large number of studies that have not been published yet, with data from a total of 10,890 unique COVID-19 patients being included in this work. Lastly, we tried to narratively describe studies that informed us on the type of diarrhea symptoms; whether diarrhea was reported as the only presenting symptom; or diarrhea as the initial symptom that preceded other symptoms. Based on our study selection process, we may have missed studies, including smaller case series that reported on this information, and studies that were published after our inclusion period, in light of the exponential number of studies in press, under review, and on preprint servers.

**Limitations of Current Evidence on Treatment-Related Adverse Effects**

Most of the information regarding GI adverse events come from indirect evidence from medications that are FDA-approved for other indications, such as the chloroquines and lopinavir/ritonavir. In particular, GI adverse events are poorly understood for both favipiravir and remdesivir, including the frequency and severity of aminotransferase elevations and incidence of GI manifestations. As ongoing clinical trials are completed regarding efficacy of therapy, additional data regarding GI adverse events will emerge.

**Evidence Gaps and Guidance for Research**

There is insufficient evidence on the impact of COVID-19 on subgroups of patients, such as patients with

| Table 3. Gastrointestinal Treatment Adverse Effects of Currently Utilized COVID-19 Therapies |
|---|---|---|---|---|
| Medication type | Medication name | Gastrointestinal | Hepatic | Major drug–drug interactions |
| Antimalarial | Chloroquine Hydroxychloroquine | Nausea, vomiting, abdominal pain, and diarrhea reported; frequency not defined | Likelihood score: D (possible rare cause of clinically apparent liver injury). Description: Rare elevations in aminotransferases. Most reactions are hypersensitivity with no known cross reactivity to hepatic injury. If this occurs, reasonable to switch between chloroquine therapies. | Substrate for CYP2D6 and CYP3A4 substrate Same as above; also substrate for CYP3A5 and CYP2C8 |
| Antiviral | Remdesivir | Not reported (limited data available) | Likelihood score: Not scored. Description: Hepatotoxicity reported; frequency not yet known. | Not a significant inducer/inhibitor of CYP enzymes |
| Antiviral | Lopinavir/ritonavir | Nausea and vomiting: 5%–10% (higher in children: 20%) Abdominal pain: 1%–10% Diarrhea: 10%–30% + dose-dependent Other: dysguesia in adults <2%, children: 25%, increased serum amylase, lipase: 3%–8% | Likelihood score: D (possible, rare cause of clinically apparent liver injury). Description: Hepatotoxicity ranges from mild elevations in aminotransferases to acute liver failure. Recovery takes 1–2 mo. Re-challenging may lead to recurrence and should be avoided if possible. | Substrate for: CYP3A4, CYP2D6 P-gp Inducer for: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, UGT1A1 Inhibitor for: CYP3A4 |
| Antiviral | Favipiravir | Nausea/vomiting: 5%–15% Diarrhea: 5% Limited data available | Likelihood score: Not scored Description: 3% prevalence, but few data available. | Inhibitor for: CYP2C8 and aldehyde oxidase Metabolized by xanthine oxidase and aldehyde oxidase |
Table 4. Guidance and Research Considerations for Future Studies of COVID-19

| Study design | A prospective inception cohort study is a favorable study design. Another study design that is informative especially when there is a need for rapid data evaluation is a retrospective inception cohort study. |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ hypocrisy
mortality due to severe pneumonia, acute respiratory distress syndrome, and multiorgan failure. Although fever, cough, and shortness of breath remain the most common presenting symptoms in affected individuals, emerging data suggest that nonpulmonary symptoms affecting the GI tract and liver may be observed. Based on systematic review and meta-analysis of 47 studies and 10,890 unique patients, gastrointestinal symptoms (ie, nausea, vomiting, abdominal pain, and diarrhea) are observed in <10% of patients with COVID-19, and abnormal liver enzymes and tests (AST, ALT, and bilirubin) are observed in approximately 15%–20% of patients with COVID-19. These findings inform time-sensitive clinical guidance in the context of this pandemic to pursue careful evaluation of patients with new-onset gastrointestinal symptoms for classic and atypical symptoms of COVID-19. All hospitalized patients with COVID-19 may benefit from liver enzyme monitoring, particularly in the context of drug treatment with known hepatotoxic potential. Further research is needed to clarify the implications of SARS-CoV-2 in stool and potential impact on transmission and clinical management.

**Supplementary Material**

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2020.05.001.

**References**

1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–574.

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533–534.

4. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343–346.

5. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020 Apr 22 [Epub ahead of print].

6. Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;158:1831–1833.e3.

7. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428–430.

8. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40:998–1004.

9. Cai Q, Huang D, Yu H, et al. Characteristics of liver tests in COVID-19 patients. J Hepatol 2020 Apr 13 [Epub ahead of print].

10. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology 2020 Apr 3 [Epub ahead of print].

11. Chen Q, Allot A, Lu Z. Keep up with the latest coronavirus research. Nature 2020;579:193.

12. Bauchner H, Golub RM, Zyike J. Editorial concern—possible reporting of the same patients with COVID-19 in different reports. JAMA 2020 Mar 6 [Epub ahead of print].

13. Schunemann HJ, Cuello C, Akl EA, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol 2019;111:105–114.

14. Sultan S, Falck-Ytter Y, Inadomi JM. The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol 2013;11:329–332.

15. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153–160.

16. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2020.

17. Barendregt JJ, Doi SA, Lee YY, et al. Meta-analysis of prevalence. J Epidemiol Community Health 2013;67:974–978.

18. Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 2018;23:60–63.

19. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.

20. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.

21. Zhao Z, Xie J, Yin M, et al. Clinical and laboratory profiles of 75 hospitalized patients with novel coronavirus disease 2019 in Hefei, China. medRxiv 2020. 2020.03.01.20029785.

22. Zhao W, Yu S, Zha X, et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study. medRxiv 2020. 2020.03.13.20035436.

23. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 Feb 19 [Epub ahead of print].

24. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020 Mar 3 [Epub ahead of print].

25. Yao N, Wang SN, Lian JQ, et al. [Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region]. Zhonghua Gan Zang Bing Za Zhi 2020;28:E003.
26. Yang P, Ding Y, Xu Z, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. medRxiv 2020. 2020.02.28. 20028068.

27. Yan S, Song X, Lin F, et al. Clinical characteristics of coronavirus disease 2019 in Hainan, China. medRxiv 2020. 2020.03.19.20038539.

28. Xu Y, Xu Z, Liu X, et al. Clinical findings in critical ill patients infected with SARS-Cov-2 in Guangdong Province, China: a multi-center, retrospective, observational study. medRxiv 2020. 2020.03.03.20030668.

29. Xu X, Yu C, Qiu C, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging 2020;47:1275–1280.

30. Xu S, Fu L, Fei J, et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv 2020. 2020.03.24.20042408.

31. Xu H, Yan L, Qiu C, et al. Analysis and prediction of false negative results for SARS-CoV-2 detection with pharyngeal swab specimen in COVID-19 patients: a retrospective study. medRxiv 2020. 2020.03.26.20043042.

32. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-19. Nature 2020 Apr 1 [Epub ahead of print].

33. Wen Y, Wei L, Li Y, et al. Epidemiological and clinical characteristics of COVID-19 in Shenzhen, the largest migrant city of China. medRxiv 2020. 2020.03.22. 20035246.

34. Wei L, Jin D, Zhang J, et al. Clinical findings of 100 mild cases of COVID-19 in Wuhan: a descriptive study. SSRN 2020:3551332.

35. Wang L, Gao YH, Lou LL, et al. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J 2020;55(4).

36. Tian S, Chang Z, Wang Y, et al. Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province, China. medRxiv 2020. 2020.03.21.20038778.

37. COVID-19 National Incident Room Surveillance Team. COVID-19 in Zhejiang, China: a retrospective, multi-center case series. QJM 2020 Mar 20 [Epub ahead of print].

38. Tabata S, Imai K, Kawano S, et al. The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the outbreak on board the Diamond Princess cruise ship in Japan. medRxiv 2020. 2020.03.18. 20038125.

39. Sun Y, Koh V, Marimuthu K, et al. Epidemiological and clinical predictors of COVID-19. Clin Infect Dis 2020 Mar 25 [Epub ahead of print].

40. Spiteri G, Fielding J, Diercke M, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Euro Surveill 2020;25(9).

41. Shu L, Wang X, Li M, et al. Clinical characteristics of 545 cases confirmed COVID-19 in Wuhan Stadium Cabin Hospital. SSRN 2020:3552844.

42. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020 Mar 25 [Epub ahead of print].

43. Rubin SJS, Falkson SR, Degner N, et al. Clinical characteristics associated with COVID-19 severity in California. J Clin Transl Sci 2020:1–9.

44. Qian QG, Yang NB, Ding F, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM 2020 Mar 20 [Epub ahead of print].

45. Qi D, Yan X, Tang X, et al. Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. medRxiv 2020. 2020.03.01.20029397.

46. Pung R, Chiew CJ, Young BE, et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet 2020; 395:1039–1046.

47. Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal symptoms and COVID-19: case-control study from the United States. Gastroenterology 2020 Apr 12 [Epub ahead of print].

48. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv 2020. 2020.02.22.20026500.

49. Ma L, Xie W, Li D, et al. Effect of SARS-CoV-2 infection upon male gonadal function: a single center-based study. medRxiv 2020. 2020.03.21.20037267.

50. Luo S, Zhang X, Xu H. Don’t overlook digestive symptoms in patients with 2019 novel Coronavirus Disease (COVID-19). Clin Gastroenterol Hepatol 2020 Mar 20 [Epub ahead of print].

51. Lu H, Ai J, Shen Y, et al. A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention. medRxiv 2020. 2020.02.19. 20025031.

52. Liu Y, Sun W, Li J, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv 2020. 2020.02.17.20024166.

53. Liu S, Luo H, Wang Y, et al. Characteristics and associations with severity in COVID-19 patients: a multicentre cohort study from Jiangsu Province, China. SSRN 2020:3548753.

54. Liu L, Liu W, Wang S, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. medRxiv 2020. 2020.03.06.20031856.

55. Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020; 69(6):997–1001.

56. Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020;55:327–331.

57. Kujawski SA, Wong KK, Collins JP, et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv 2020. 2020.03.09.20032896.
71. Chen X, Zheng F, Qing Y, et al. Epidemiological and clinical characteristics of 74 cases of coronavirus disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002–1009.

72. Chen T, Wu D, Chen H, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002–1009.

73. Chen Q, Quan B, Li X, et al. A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019. J Med Virol 2020 Mar [Epub ahead of print].

74. Chen D, Li X, Song Q, et al. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020. 2020.02.27.20028530.

75. Arentz M, Yin E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020 Mar 19 [Epub ahead of print].
90. Kaletra (lopinavir and ritonavir) tablets and oral solution [prescribing information]. North Chicago, IL: AbbVie Inc, March 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf; Accessed April 10, 2020.

91. Lopinavir. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012.

92. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. MedRxiv 2020;2020.03.17.20037432.

93. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020 Mar 18 [Epub ahead of print].

94. Higgins PDR, Ng S, Danese S, et al. The risk of SARS-CoV-2 in immunosuppressed IBD patients. Crohns Colitis 2020;360:2; otaa026.

95. Rodriguez-Lago I, Ramirez de la Piscina P, Elorza A, et al. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology 2020 Apr 21 [Epub ahead of print].

96. Rubin DT, Feuerstein JD, Wang AY, et al. AGA Clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology 2020 Apr 10 [Epub ahead of print].

97. Rubin DT, Abreu MT, Rai V, et al. Management of patients with Crohn’s disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting. Gastroenterology 2020 Apr 6 [Epub ahead of print].

98. Norsa L, Indriolo A, Sansotta N, et al. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology 2020 Apr 2 [Epub ahead of print].

99. Peyrin-Biroulet L. Will the quality of research remain the same during the COVID-19 pandemic? Clin Gastroenterol Hepatol 2020 Mar 30 [Epub ahead of print].

100. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf; Accessed April 20, 2020.

101. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.

102. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1580 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5).

103. Hohshe ML, DeBolt C1, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–936.

104. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020 Mar 10 [Epub ahead of print].

105. Momattin H, Al-Ali AY, Al-Tawfiq JA. A systematic review of therapeutic agents for the treatment of the Middle East Respiratory syndrome coronavirus (MERS-CoV). Travel Med Infect Dis 2019;30:9–18.

106. Yao TT, Qian JD, Zhu WY, et al. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020 Feb 27 [Epub ahead of print].

107. AI-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020;34:101615.

108. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.

109. Cai Q, Yang M, Liu D, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020. https://10.1016/j.eng.2020.03.007. Online ahead of print.

110. U. S. Food and Drug Administration. KALETRA (lopinavir and ritonavir) prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021251s052_021906s046lbl.pdf; Accessed April 27, 2020.

111. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD); 2012. Lopinavir. [Updated 2017 Sep 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547961/. Accessed April 27, 2020.

112. U. S. Food and Drug Administration. ARALEN (chloroquine phosphate) prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/006002s044lbl.pdf. Accessed April 27, 2020.

113. U. S. Food and Drug Administration. PLAQUENIL (hydroxychloroquine sulfate) prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009768s037s045s047lbl.pdf; Accessed April 27, 2020.

Correspondence
Address correspondence to: American Gastroenterological Association, National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. e-mail: ewilson@gastro.org.

Conflicts of interest
All members were required to complete the disclosure statement. These statements are maintained at the AGA headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report. None of the panel members had any conflict relevant to this guideline.

Funding
This document represents the official recommendations of the American Gastroenterological Association (AGA) and was developed by members of the AGA Clinical Guideline Committee and Clinical Practice Update Committee and approved by the AGA Governing Board. No internal or external funding was provided for the development of this guideline. Expiration date: 3 months.
Additional records from websites (FDA, NIH) and (n =12)

Literature search for: COVID MeSH term (n =2730)

Additional records from MedRxiv, LitCovid, SSRN (n = 4760)
personal communication (n=1)

Records after de-duplication COVID MeSH (n = 1655)
Other Combined Sources (n= 4760)

Titles/Abstracts Screened (n=6415)

Title and abstract excluded (n=6186)
(n =   )

Full-text articles assessed for eligibility (n=229)

Full-text articles excluded (n =173)

Total Studies included (n=56)

Supplementary

Figure 1. PRISMA 2009 Flow Diagram

Supplementary

Figure 2. The matrix used in the selection of the Chinese studies. The X-axis represents the studies. The Y axis represent the hospitals included in the study. The size of the bubble reflects the number of patients in the study. Two studies by Guan et al\textsuperscript{101,102} were not included in the plot as they included patients from more than 500 hospitals from 30 or more provinces without providing the names of the hospitals.
Supplementary Figure 3. Forest plot of the prevalence of diarrhea in all admitted patients regardless of the timing of diarrhea.
Supplementary Figure 4. Forest plot of the prevalence of diarrhea as one of the initial symptoms in all patients regardless of hospitalization status.
Supplementary Figure 5. Forest plot of the prevalence of diarrhea as one of the initial symptoms in all admitted patients.

Supplementary Figure 6. Forest plot of the prevalence of diarrhea in outpatients regardless of the timing of diarrhea.
**Supplementary Figure 7.** Forest plot of the prevalence of nausea/vomiting as one of the initial symptoms in all patients regardless of hospitalization status.

**Supplementary Figure 8.** Forest plot of the prevalence of abdominal pain as one of the initial symptoms in all patients regardless of hospitalization status.
**Supplementary Figure 9.** Forest plot of the prevalence of elevated AST.

**Supplementary Figure 10.** Forest plot of the prevalence of elevated ALT.
Supplementary Figure 11. Forest plot of the prevalence of elevated total bilirubin.
## Supplementary Table 1. Summary of Included Studies

| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations
|-----------------------|-------------------------|-------------------------------|---------------------|
| **Hubei Province, China** | Luo, 2020 | n = 1141 | Diarrhea: 6.0% (n = 68) | AST (183 patients) m 65.8 ± 12.7 |
| Zhongnan Hospital (Wuhan) | Dates: 01/01/2020-02/20/2020 | Survival: 3.8% (7/183) death, 96.2% recovered | Present on admission | ALT (183 patients) m 66.4 ± 13.2 |
| Last follow-up: NR | Inclusion: Inpatients with COVID-19 (throat swab RT-PCR). All patients received chest CT. Details only provided for the 183 patients with GI symptoms. | Abdominal pain: 3.9% (n = 45) | | |
| | Age: m 53.8 y (183 patients) | Nausea: 11.7% (n = 134) | | |
| | Sex: 44.3% (81/183) females | Vomiting: 10.4% (119) | | |
| | GI/liver comorbidities: NR | Nausea and vomiting: 3.2% (n = 37) | | |
| | Disease severity: NR | | | |
| | | | | |
| **Zhou, 2020** | Jinyintan Hospital (Wuhan) | n = 191 | Diarrhea: 4.7% (9/191) | AST: NR |
| | Dates: 12/29/2019-01/31/2020 | Survival: 28.3% death, 71.8% discharged | Present on admission | ALT >40: 31.2% (59/189) |
| | Last follow-up: 01/31/2020 | Inclusion: Inpatients with COVID-19 (confirmed with RT-PCR) who died or were discharged. Patients without key information excluded (9). | 2 died and 7 discharged | 26 died and 33 discharged |
| | | Age: M 56 y (IQR, 46–67 y) | Nausea/vomiting: 3.7% (7/191) | Total bilirubin: NR |
| | | Sex: 37.7% females | Present on admission | |
| | | GI/liver comorbidities: NR | 3 died and 4 discharged | |
| | | Disease severity: General 28%, severe: 35%, critical 28% | Abdominal pain: NR | |
| | | | | |
| **Zhang, 2020** | Wuhan No. 7 Hospital (Wuhan) | n = 140 | Diarrhea: 12.9% (18/139) | AST, ALT, and bilirubin: NR |
| | Dates: 1/16/2020-02/03/2020 | Survival: NR | Present on admission | |
| | Last follow-up: NR | Inclusion: Inpatient with COVID-19 (pharyngeal swab PCR) based on symptoms and chest x-ray. | 9/82 nonsevere cases and 9/57 severe cases | |
| | | Age: 57 y (range, 25–87 y) | Nausea: 17.3% (24/139) | |
| | | Sex: 49.3% females | Present on admission | |
| | | GI/liver comorbidities: 5.7% fatty liver and abnormal liver function, 5.0% chronic gastritis and gastric ulcer, 4.3% cholelithiasis, 6.4% cholecystectomy 5.0% appendectomy, 0.7% hemorrhoidectomy, 4.3% tumor surgery | 19/82 nonsevere cases and 5/57 severe cases | |
| | | Disease severity: severe 41.4% and nonsevere 58.6% | Vomiting: 5.0% (7/139) | |
| | | | Present on admission | |
| | | | 5/82 nonsevere cases and 2/57 severe cases | Belching 5.0% (7/139) | |
| | | | Present on admission | |
| | | | 4/82 nonsevere cases and 3/57 severe cases | Present on admission | |
| | | | Abdominal pain: 5.8% (8/139) | | |
| | | | Present on admission | | |
| | | | 2/82 nonsevere cases and 6/57 severe cases | Other pathogens were detected including *Mycoplasma pneumoniae* in 5, respiratory syncytial virus in 1, Epstein-Barr virus in 1. | |
| Study characteristics                  | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations<sup>2</sup> |
|---------------------------------------|-------------------------|----------------------------------|----------------------------------|
| **Chen, 2020<sup>72</sup>**           |                         | Diarrhea: 28.1% (n = 77)         | AST >40: 30.7% (84)               |
| Tongji Hospital (Wuhan)               |                         | Present on admission             | 59/113 deceased and 25/161 discharged |
| Dates: 01/13/2020-02/12/2020          |                         | 27/113 deceased and 50/161 discharged | M 30 (IQR, 22–46). Deceased M 45 (IQR, 31–67) and discharged M 25 (IQR, 20–33) |
| Last follow-up: 02/28/2020            |                         | Nausea: 8.8% (n = 24)            | ALT >41: 21.9% (60)               |
|                                       |                         | Present on admission             | 30/113 deceased and 30/161 discharged |
|                                       |                         | 8/113 deceased and 16/161 discharged | M 23 (IQR, 15–38). Deceased M 28 (IQR, 18–47) and discharged M 20 (IQR, 15–32) |
|                                       |                         | Vomiting: 5.8% (n = 16)          | Bilirubin M 0.6 (IQR, 0.4–0.8). Deceased M 0.7 (IQR, 0.6–1.0) and discharged M 0.5 (IQR, 0.3–0.7) |
|                                       |                         | Present on admission             | NR                               |
|                                       |                         | Abdominal pain: 6.9% (n = 19)    |                                   |
|                                       |                         | Present on admission             |                                   |
|                                       |                         | 6/113 deceased and 10/161 discharged |                                   |
|                                       |                         | Diarrhea: 2.1% (28)             |                                   |
|                                       |                         | Present on admission             |                                   |
|                                       |                         | Loss of appetite: 4.2%           |                                   |
|                                       |                         | Present on admission             |                                   |
|                                       |                         | Nausea, vomiting, and abdominal pain: NR |                                   |

| **Xu, 2020<sup>31</sup>**            |                         |                                 |                                   |
| Tongji Hospital (Wuhan)               |                         |                                 |                                   |
| Dates: 1/15/2020-2/19/2020            |                         |                                 |                                   |
| Last follow-up: NR                    |                         |                                 |                                   |
|                                       |                         |                                 |                                   |
|                                       |                         |                                 |                                   |

| **Shi, 2020<sup>42</sup>**            |                         |                                 |                                   |
| Renmin Hospital (Wuhan)               |                         |                                 |                                   |
| Dates: 1/1/2020-2/10/2020             |                         |                                 |                                   |
| Last follow-up: 2/15/2020             |                         |                                 |                                   |
|                                       |                         |                                 |                                   |
|                                       |                         |                                 |                                   |

<sup>2</sup> AST > 40: 30.7% (84) / ALT > 41: 21.9% (60) / Bilirubin M 0.6 (IQR, 0.4–0.8).
| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations |
|-----------------------|-------------------------|---------------------------------|---------------------|
| Han, 2020<sup>62</sup> Wuhan No.1 Hospital Dates: 1/4/2020-2/3/2020 Last follow-up: NR | n = 108 Survival: NR death, NR recovered Inclusion: Inpatients COVID-19 (confirmed by RT-PCR) with mild pneumonia, no history of other lung infection, initial CT performed. Exclusion: CT scans performed as follow-up for COVID-19 pneumonia, or chest CT image quality insufficient for image analysis Age: mean 45 y (range, 21–90 y) Sex: 64.8% females GI/liver comorbidities: Not specified Disease severity: NR | Diarrhea: 14% (15/108) Abdominal pain, nausea, vomiting: NR | No laboratory data reported |
| Xu, 2020<sup>30</sup> Union Hospital (Wuhan) Dates: 1/25/2020-2/20/2020 Last follow-up: 2/20/2020 | n = 355 Survival: NR Inclusion: Inpatients with COVID-19, confirmed based on RT-PCR. Age: 45.1% aged <50 y, 41.7% aged 50–69 y, 13.2% aged ≥70 y Sex: 45.6% females GI/liver comorbidities: Not specified Disease severity: NR | Diarrhea: 36.6% (130/355) Abdominal pain, nausea, vomiting NR | AST: 28.7% (102/355) m 40.8 (range, 10–475) ALT: 25.6% (91/355) m 35.0 (range, 1–414) Total bilirubin: 18.6% (66/355) m 0.83 (range, 0.1–29.9) |
| Ma, 2020<sup>49</sup> Wuhan Leishenshan Hospital (Wuhan) Dates: 3/5/2020-3/18/2020 Last follow-up: NR | n = 81 Survival: NR Inclusion: Inpatients with COVID-19 (RT-PCR on nasal and pharyngeal swabs) Age: M 38 y (IQR, 34.5–42.5 y) Sex: 0% female GI/liver comorbidities: NR Disease severity: 2.5% mild, 86.4% moderate, 8.6% severe, 2.5% critical. | Diarrhea: 7.41% (6/81) Nausea/vomiting: NR Abdominal pain: NR | AST/ALT - composite report 31/81 abnormal but no threshold AST M 23 (IQR, 12–453) ALT M 43 (IQR, 13–799) Bilirubin: NR |
| Liu, 2020<sup>34</sup> General Hospital of Central Theater Command of PLA (Wuhan) Dates: 2/6/2020 - 2/14/2020 Last follow-up: NR | n = 153 (85 tested negative but had symptoms, we did not include those patients) Survival: NR Inclusion: Inpatients with COVID-19 (RT-PCR on pharyngeal swabs) Age: M 55 y (IQR, 38.3–65 y) Sex: 39.2% female GI/liver comorbidities: NR Disease severity: NR | Diarrhea: 9.2% (14/153) Present on admission Nausea: 1.3% (2/153) Present on admission Vomiting: 2% (3/153) Present on admission Abdominal pain: 0.4% (1/153) Present on admission | AST, ALT, and bilirubin: NR |
## Supplementary Table 1. Continued

| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestationsa |
|-----------------------|-------------------------|--------------------------------|----------------------|
| **Huang, 2020**51     | n = 36                  | Diarrhea: 8.33% (3/36)         | AST: >40 58.1% (18/31) |
| The Fifth Hospital of Wuhan (Wuhan) | Survival: 100% death | Present on admission | M 43 (IQR, 30–51) |
| Dates: 1/21/2020-2/10/2020 | Inclusion: Patients with COVID-19 (RT-PCR) | Nausea: NR | ALT: >50 13.3% (4/30) |
| Last follow-up: 2/14/2020 | Age: mean 69.22 y (SD 9.64 y; range, 50–90 y) | Vomiting: NR | M 26 (IQR, 18–38) |
|                        | Sex: 30.56% female | Abdominal pain: NR | Bilirubin: >25 12.9% (4/31) |
|                        | GI/liver comorbidities: NR | | M 11.2 (IQR, 7.5–19.2) |
| **Mao, 2020**18        | n = 214                 | Diarrhea: 19.2% (41/214)       | AST 26 (8–8191) |
| Union Hospital (Wuhan) | Survival: 1 died but not fully reported. | Present on admission | Severe 34 (8–8191), non-severe 23 (9–244) |
| Dates: 1/16/2020-2/19/2020 | Inclusion: Inpatients with COVID-19 (RT-PCR from throat) | Severe disease 14.8% (13/88), nonsevere disease 22.2% (28/126) | ALT 26 (5–1933) |
| Last follow-up: NR    | Age: m 52.7 ± 15.5 y   | Abdominal pain: 4.7% (10/214), not included in the analysis | Severe 32.5 (5–1933), non-severe 23 (6–261) |
|                        | Sex: 59.3% female      | Present on admission | |
|                        | GI/liver comorbidities: NR | | |
|                        | Disease severity: NR   | | |
| **Ai, 2020**76         | n = 102                 | Diarrhea: 14.3% (15)           | AST >40: 25.5% (26/102) |
| Xiangyang No.1 People’s Hospital | Survival: 2.9% died, 6.9% survived, 90.2% still hospitalized | Present on admission | Mean 30.59 (SD 15.03) |
| Dates: Cross-sectional study 2/9/2020 | Inclusion: Inpatients with laboratory-confirmed COVID-19 | Diarrhea was the first symptom in 2 patients | ALT >50: 19.6% (20/102) |
|                        | Age: m 50.4 ± 16.9 y   | Nausea: 8.8% (9)               | Mean 27.77 (SD 21.13) |
|                        | Sex: 49.1% females     | Present on admission | Total bilirubin NR |
|                        | GI/liver comorbidities: NR | Vomiting: 2.0% (2) | |
|                        | Disease severity: NR   | Present on admission | |
| **Liu, 2020**52        | n = 109                 | Abdominal pain: 2.9% (3)      | |
| Central Hospital of Wuhan (Wuhan) | Survival: 28.4% died, NR otherwise | Present on admission | |
| Dates: 1/2/2020-2/1/2020 | Inclusion: Inpatient with COVID-19 confirmed based on RT-PCR on throat swab | Diarrhea 11% (12) | AST: M 30 (IQR, 21–40) |
| Last follow-up: NR    | Age: M 62.5 y (IQR, 47.25–65 y) | Present on admission | No ARDS 29 (19–38); ARDS 31 (25–44) |
|                        | Sex: 33.3% females     | 6/12 with ARDS and 6/12 with no ARDS | ALT: M 23 (IQR, 15–36) |
|                        | GI/liver comorbidities: NR | Nausea, vomiting and abdominal pain: NR | No ARDS 23 (14–41); ARDS 24 (16–31) |
|                        | Disease severity: NR   | | Total bilirubin NR |
| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations |
|-----------------------|-------------------------|--------------------------------|----------------------|
| **Shu, 2020**<sup>11</sup> | n = 545 | Diarrhea: 8.9% (49) | AST > 45: 6.4% (35) |
| Cabin Hospital of Wuhan Stadium (Wuhan) | Survival: 85.9% discharged, 14.1% still hospitalized, 0% died | Present on admission | M 32.1 (IQR, 24.5–36.4) |
| Dates: 2/13/2020-2/29/2020 | Inclusion: Inpatient with COVID-19 confirmed based on RT-PCR. Severe cases requiring transfer were excluded. | Nausea or vomiting: 0% (0) | ALT > 50: 7.5% (41) |
| Last follow-up: NR | Age: M 50 y (IQR, 38–58 y) | Present on admission | Bilirubin > 1.2: 34.6% (189) |
| | Sex: 51.2% females | | M 1.1 (IQR, 0.8–1.3) |
| | Gl/liver comorbidities: 0 chronic liver disease | | |
| | Disease severity: 2.9% mild, 97.1% moderate, 0 severe (excluded). | | |
| **Wei, 2020**<sup>14</sup> | n = 100 | Diarrhea: 2% (2) | AST elevated: 5 (5%) |
| Wuhan Integrated Chinese and Western Medicine Hospital (Wuhan) | Survival: 3% died, 1% discharged, 96% still hospitalized. | Present on admission | ALT elevated: 17 (17%) |
| Dates: 2/1/2020-2/28/2020 | Inclusion: Inpatients with COVID-19 confirmed based on RT-PCR. Only mild cases. | Vomiting: 2% (2) | Total bilirubin abnormal: 0 (0%) |
| Last follow-up: NR | Age: m 49.1 ± 17.2 y | Present on admission | |
| | Sex: 60% females | | |
| | Gl/liver comorbidities: 9% digestive system diseases, 6% chronic gastritis | | |
| | Disease severity: 100% mild. | | |
| **Other Chinese Provinces** | **Chen, 2020**<sup>7</sup> | **Zhao, 2020**<sup>21</sup> | **AST, ALT, and bilirubin: NR** |
| **Chen, 2020**<sup>7</sup> | n = 9 | Diarrhea: 22.2% (2) | AST > 40: 18.7% (14) |
| The First Affiliated Hospital of Wanan Medical College (Wuhu) Anhui | Survival: 100% discharged | Nausea/vomiting: 0% (0) | M 27 (IQR, 21–37) |
| Dates: NA (Case series) | Inclusion: Inpatients with COVID-19 confirmed on RT-PCR via swab | Abdominal pain: 0% (0) | ALT > 40: 20% (15) |
| | Age: range, 25–56 y | | M 23 (IQR, 14–43) |
| | Sex: 44.4% females | | Bilirubin > 1.2: 16% (12) |
| | Gl/liver comorbidities: NR | | M 0.85 (IQR, 0.65–1.06) |
| | Disease severity: 55.6% moderately ill and 44.4% severely ill | | ALT, ALT, and total bilirubin were not associated with elevated interleukin-6 (a study outcome) |
### Supplementary Table 1. Continued

| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations$^a$ |
|-----------------------|-------------------------|---------------------------------|-------------------------|
| Zhao, 2020$^{22}$     | Beijing YouAn Hospital  | n = 77                           | Diarrhea: 1.3% (1)      | AST > 40: 26.0% (20)   |
| Beijing               | Beijing Dates: 1/21/2020-2/8/2020 Last follow-up: 2/29/2020 | Survival: 6.5% died, 83.1% discharged, 10.4% still hospitalized | Present on admission | 11/57 non-severe and 9/20 severe |
|                       |                         | Inclusion: Inpatients with COVID-19 based on RT-PCR. | 1/57 nonsevere and 0/20 severe | M 19 (IQR, 21–42) |
|                       |                         | Age: m 52 ± 2 y Sex: 55.8% females GI/liver comorbidities: 10.4% digestive diseases | Nausea or vomiting: 7.8% (6) | ALT >40: 33.8% (26) |
|                       |                         | Disease severity: 74% non-severe, 26% severe | Present on admission | 17/57 non-severe and 9/20 severe |
|                       |                         | n = 55                           | 3/57 nonsevere and 3/20 severe | M 28 (IQR, 20–46) |
|                       |                         | Survival: 3.6% died              | Abdominal pain: NR      | Bilirubin |
| Yang, 2020$^{26}$     | Chinese PLA General Hospital Beijing Dates: 12/27/2019-2/18/2020 Last follow-up: 2/18/2020 | n = 55                           | Diarrhea: 3.6% (2)      | AST, ALT, and bilirubin: NR   |
|                       | Beijing                | Survival: 3.6% died              | Present on admission | 0/21 of the patients without pneumonia on admission and 2/34 of the patients with pneumonia |
|                       | Beijing                | Inclusion: Inpatients with COVID-19, confirmed with RT-PCR. | Nausea, vomiting, and abdominal pain: NR |
|                       | Beijing                | Age: M 44 y (IQR, 34–54 y, range, 3–85 y) Sex: 40% females GI/liver comorbidities: 1.8% chronic liver disease | Disease severity: 74% non-severe, 26% severe |
|                       | Beijing                | Disease severity: 38.2% mild, 36.4% common, 23.6% severe, and 1.8% extremely severe. | N = 83 | AST, ALT, and bilirubin: NR |
| Li, 2020$^{56}$       | The Second Affiliated Hospital of Chongqing Medical University, Chongqing Dates: 1/2020-2/2020 Last follow-up: 2/18/2020 | Survival: NR | Diarrhea and abdominal pain: 8.4% (7) | AST, ALT, and bilirubin: NR |
|                       | Chongqing              | Inclusion: Inpatients with COVID-19 and at least one abnormal CT scan. Patients with normal CT were excluded (8). | Present on admission | Nausea or vomiting: NR |
|                       | Chongqing              | Age: m 45 ± 12.3 y Sex: 47% females GI/liver comorbidities: NR | Disease severity: 69.9% ordinary, and 30.1% severe/critical | Disease severity: 69.9% ordinary, and 30.1% severe/critical |
| Qi, 2020$^{45}$       | Chongqing Public Health Medical Center, Chongqing Three Georges Central Hospital, and Qianjiang Central Hospital of Chongqing Chongqing Dates: 1/19/2020-2/16/2020 Last follow-up: 2/16/2020 | n = 267                           | Diarrhea: 3.7% (10)      | AST >35: 7.2% (19)   |
|                       | Chongqing              | Survival: 1.5% died, 38.6% discharged, 59.9% still hospitalized. | Present on admission | 9/217 non-severe and 10/50 severe |
|                       | Chongqing              | Inclusion: Inpatients with COVID-19 based on RT-PCR. Excluded patients with missing data (42). | Nausea or vomiting: 2.2% (6) | ALT >40: 7.5% (20) |
|                       | Chongqing              | Age: M 48 y (IQR, 25–65 y) Sex: 44.2% females GI/liver comorbidities: GI diseases 4.5% Disease severity: 81.3% non-severe and 18.7% severe | Present on admission | 10/217 non-severe and 10/50 severe |
|                       | Chongqing              | Disease severity: 81.3% non-severe and 18.7% severe | Diarrhea: 3.7% (10) | Bilirubin >1.5: 2.2% (6) |
|                       | Chongqing              | GI/liver comorbidities: GI diseases 4.5% Disease severity: 81.3% non-severe and 18.7% severe | Abdominal pain: NR | 3/217 non-severe and 3/50 severe |

$^a$GI manifestations and liver manifestations are detailed in the study; AST, ALT, and bilirubin are not available in all cases.
### Supplementary Table 1. Continued

| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations$^a$ |
|-----------------------|-------------------------|---------------------------------|-------------------------|
| **Xu, 2020$^{29}$**  |                         |                                 |                         |
| Guangzhou Eighth People's Hospital (Guangzhou) Guangdong | n = 90                    | Diarrhea: 5.6% (5)              | NR                     |
| Dates: 1/23/2020-2/4/2020 | Survival: NR            | Vomiting: 5.6% (5)              |                         |
| Last follow-up: NR    | Inclusion: Inpatients with COVID-19 based on RT-PCR who had baseline chest CT. | Nausea: 2.2% (2)           |                         |
| Age: M 50 y (range, 18–86 y) | Sex: 56.7% females      |                                 |                         |
|                       | GI/liver comorbidities: NR |                                 |                         |
|                       | Disease severity: NR     |                                 |                         |
|                       | Diarrhea: 5.6% (5)       |                                 |                         |
|                       | Vomiting: 5.6% (5)       |                                 |                         |
|                       | Nausea: 2.2% (2)         |                                 |                         |
| **Lin, 2020$^{55}$**  |                         |                                 |                         |
| The Fifth Affiliated Hospital of Sun Yat-sen University (Zhuhai) Guangdong | n = 95                   | Diarrhea: 24.2% (23)           | AST >35 for females and >40 for males: 4.2% (4) |
| Dates: 1/17/2020-2/15/2020 | Survival: 0% died, 38.9% discharged, 61.1% still hospitalized | 5.2% (5) present on admission. | ALT >40 for females and >50 for males: 5.3% (5) |
| Last follow-up: 2/15/2020 | Inclusion: Inpatients with confirmed COVID-19. | Loose or watery stool, 2-10 bowel movements daily. | Bilirubin >1.5: 23.2% (22) |
|                       | Age: 45.3 ± 18.3 y       | Vomiting: 4.2% (4)              |                         |
|                       | Sex: 52.6% females       | 0% (0) present on admission.    |                         |
|                       | GI/liver comorbidities: NR | Nausea: 17.9% (17)            |                         |
|                       | Disease severity: 78.9% non-severe, 21.1% severe | 3.2% (3) present on admission. |                         |
|                       | Abdominal pain: 2.1% (2) | Abdominal pain: 2.1% (2)       |                         |
|                       | Epigastric discomfort.   | 0% (0) present on admission.    |                         |
|                       | 11 patients with GI symptoms did not have pneumonia. | Viral RNA detected in 31/65 patients including 22/42 who had GI symptoms and 9/23 who did not have GI symptoms. |                         |
|                       | ALT, AST, and bilirubin: NR | ALT, AST, and bilirubin: NR    |                         |
|                       | Diarrhea: 7.0% (29)      | ALT, AST, and bilirubin: NR    |                         |
|                       | Present on admission.    | ALT, AST, and bilirubin: NR    |                         |
|                       | 23/381 of mild/moderates and 6/36 of severe/critical | ALT, AST, and bilirubin: NR    |                         |
|                       | Nausea, vomiting, and abdominal pain: NR | ALT, AST, and bilirubin: NR    |                         |
| **Wen, 2020$^{33}$**  |                         |                                 |                         |
| All Shenzhen City Guangdong | n = 417                |                                 |                         |
| Dates: 1/1/2020-2/28/2020 | Survival: 0.7% died, 71.7% discharged, 27.6% still hospitalized. |                                 |                         |
| Last follow-up: 2/28/2020 | Inclusion: Inpatients with COVID-19 based on RT-PCR. |                                 |                         |
|                       | Age: m 45.4 y            |                                 |                         |
|                       | Sex: 52.8% females       |                                 |                         |
|                       | GI/liver comorbidities: NR |                                 |                         |
|                       | Disease severity: 8.9% mild, 82.5% moderate, 8.6% severe/critical |                                 |                         |

$^a$ ALT, AST, and bilirubin values are not provided.
| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations |
|-----------------------|-------------------------|---------------------------------|----------------------|
| Xu, 2020<sup>28</sup> | n = 45 | Diarrhea: 0% (0) | AST or ALT >40: 37.8% (17) |
| First Affiliated Hospital of Guangzhou Medical University (Guangzhou), Dongguan People’s Hospital (Dongguan), Foshan First People’s Hospital (Foshan), Huizhou Municipal Central Hospital (Huizhou), First Affiliated Hospital of Shantou University Medical College (Shantou), Affiliated Hospital of Guangdong Medical University (Zhanjiang), Zhongshan City People’s Hospital (Zhongshan) Guangdong Dates: 2/28/2020 Last follow-up: 2/28/2020 | Survival: death 0.2%, 24.4% discharged, 73.3% still hospitalized. Inclusion: Critically ill patients with COVID-19 pneumonia. Age: m 56.7 ± 15.4 y Sex: 35.6% females GI/liver comorbidities: NR Disease severity: 100% critical | Present on admission | AST (n = 44) M 27 (IQR, 22.0–39.5) ALT (n = 44) M 29 (IQR, 20.1–50.0) Bilirubin (n = 44) M 0.91 (IQR, 0.61–1.3) |
| Yan, 2020<sup>27</sup> | n = 168 | Diarrhea: 7.1% (12) | AST >40: 17.3% (18/104) |
| All Hainan Province Hainan Dates: 1/22/2020-3/13/2020 Last follow-up: 3/13/2020 | Survival: 3.6%, 1.2% still hospitalized, 95.2% discharged. Inclusion: Inpatient with COVID-19 based on RT-PCR. Age: M 51 y (IQR, 36–62 y) Sex: 51.8% females GI/liver comorbidities: 3.6% chronic liver disease Severity: 78.6% nonsevere, 21.4% severe | Present on admission 8/132 non-severe, 4/36 severe Vomiting: 4.2% (7) | 7/75 non-severe, 11/29 severe ALT >40: 8.0% (9/112) 5/81 non-severe, 4/31 severe Bilirubin >1.5: 0 M 0.51 (IQR, 0.37–0.78) |
| Wang, 2020<sup>35</sup> | n = 18 | Diarrhea: 16.7% (3) | AST or ALT elevated: 25% (4) |
| First Affiliated Hospital of Zhengzhou University (Zhengzhou) Henan Dates: 1/21/2020-2/7/2020 Last follow-up: 2/7/2020 | Survival: 0 died, 33.3% discharged, 66.7% still hospitalized Inclusion: Inpatients with COVID-19 Age: M 39 y (IQR, 29–55 y) Sex: 50% females GI/liver comorbidities: NR Disease severity: NR | Present on admission Vomiting, nausea, abdominal pain: NR | Bilirubin: NR |
| Study characteristics                  | Patient characteristics                                                                 | Gastrointestinal manifestations                                                                 | Liver Manifestations² |
|--------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------|
| Chen, 2020⁷¹<br>First Hospital of Changsha (Changsha) and Loudi Central Hospital (Loudi) Huanan<br>Dates: 1/23/2020-2/14/2020<br>Last follow-up: 2/20/2020 | n = 291<br>Survival: 0.7% died, 54.6% discharged, 44.7% still hospitalized<br>Inclusion: Inpatients with COVID-19 based on RT-PCR.<br>Age: M 46 y (IQR, 34–59 y, range, 1–84 y)<br>Sex: 50.2% females<br>GI/liver comorbidities: 5.2% chronic liver disease<br>Disease severity: 10% mild, 72.8% moderate, 17.2% severe/critical | Diarrhea: 8.6% (25)<br>Present on admission<br>3/29 mild, 17/212 moderate, 5/50 severe/critical<br>Nausea or vomiting: 5.8% (17)<br>Present on admission<br>6/29 mild, 9/212 moderate, 2/50 severe/critical<br>Abdominal pain: 0.3% (1)<br>Present on admission<br>0/29 mild, 0/212 moderate, 1/50 severe/critical | AST >37: 15.1% (44)<br>5/29 mild, 23/212 moderate, 16/50 severe/critical<br>M 24.7 (IQR, 19.9–31.4)<br>ALT >42: 10.3% (30)<br>4/29 mild, 16/212 moderate, 10/50 severe/critical<br>M 20.7 (IQR, 14.9–28.9)<br>Bilirubin >1.2: 9.3% (27)<br>4/29 mild, 17/212 moderate, 6/50 severe/critical<br>M 0.6 (IQR, 0.5–0.9)<br>AST (387) m 23.3 ± 18.5<br>m 27.3 ± 14.9 in mild/ asymptomatic, 32.3 ± 17.5 in moderate, 42.9 ± 28.6 in severe/critically ill<br>ALT (420) m 31.0 ± 22.4<br>m 26.8 ± 21.6 in asymptomatic/mild, m 31.2 ± 21.1 in moderate, m 39.3 ± 32.5 in severe/critically ill<br>Bilirubin (460) m 0.6 ± 0.4<br>m 0.7 ± 0.5 mild/asymptomatic, m 0.6 ± 0.4 moderate, m 0.7 ± 0.4 severe/critically<br>ALT m 40.6<br>m 27.8 in mild/moderate and m 57.1 in severe/critical<br>Bilirubin m 19.5<br>m 19.0 in mild/moderate and m 22.4 in severe/critical<br>AST: NR |
| Liu, 2020⁵³<br>All Jiangsu Province Jiangsu<br>Dates: 1/10/2020-2/18/2020<br>Last follow-up: 2/18/2020 | n = 620<br>Survival: 0 died, 3.2% in ICU, 56.1% still hospitalized, 40.6% discharged<br>Inclusion: Inpatient with COVID-10 based on RT-PCR. Patients without records excluded.<br>Age: m 44.5 ± 17.2 y<br>Sex: 47.4% females<br>GI/liver comorbidities: NR<br>Disease severity: 15.6% asymptomatic/mild, 75.8% moderate, 8.5% severe/critical | Diarrhea: 8.5% (53)<br>Present on admission<br>4/97 asymptomatic/mild, 43/469 moderate, 6/53 severe/critically ill<br>Nausea, vomiting, and abdominal pain: NR | AST (387) m 23.3 ± 18.5<br>m 27.3 ± 14.9 in mild/asymptomatic, 32.3 ± 17.5 in moderate, 42.9 ± 28.6 in severe/critically ill<br>ALT (420) m 31.0 ± 22.4<br>m 26.8 ± 21.6 in asymptomatic/mild, m 31.2 ± 21.1 in moderate, m 39.3 ± 32.5 in severe/critically ill<br>Bilirubin (460) m 0.6 ± 0.4<br>m 0.7 ± 0.5 mild/asymptomatic, m 0.6 ± 0.4 moderate, m 0.7 ± 0.4 severe/critically<br>ALT m 40.6<br>m 27.8 in mild/moderate and m 57.1 in severe/critical<br>Bilirubin m 19.5<br>m 19.0 in mild/moderate and m 22.4 in severe/critical<br>AST: NR |
| Fan, 2020⁹⁷<br>Shenyang Chest Hospital (Shenyang) Liaoning<br>Dates: 1/20/2020-3/15/2020<br>Last follow-up: NR | n = 55<br>Survival: 100% recovered<br>Inclusion: Recovered hospitalized COVID-19 patients, based on RT-PCR.<br>Age: m 46.8 y<br>Sex: 45.5% females<br>GI/liver comorbidities: NR<br>Disease severity: 85.4% mild, 14.5% severe | Diarrhea: 10.9% (6)<br>Present on admission<br>4/47 mild/moderate, 2/8 severe/critical<br>Vomiting: 7.3% (4)<br>2/47 mild/moderate, 2/8 severe/critical<br>Abdominal pain: NR | AST >46: 40% (16)<br>Occurred as early as the 4th day up to the 26th day.<br>ALT >66: 52.5% (21)<br>Occurred as early as the 4th day up to the 26th day.<br>Bilirubin >1.2: 25% (10)<br>Occurred as early as the 4th day up to the 16th day. Mostly slight increase.<br>Liver injury occurred in 17/22 critical cases 5/18 noncritical cases. |
| Yao, 2020⁵⁵<br>Tangdu Hospital (Xi’an) Shaanxi<br>Dates: 1/21/2020-2/21/2020<br>Last follow-up: NR | n = 40<br>Survival: Inpatients with COVID-19. No baseline LFT abnormality.<br>Age: m 53.9 ± 15.8 y (range, 22–83 y)<br>Sex: 37.5% females<br>GI/liver comorbidities: 0% liver disease or damage.<br>Disease severity: 45% non-severe, and 55% severe | Diarrhea: 7.5% (3)<br>Occurred as early as the 4th day up to the 26th day.<br>Vomiting and abdominal pain: NR | AST >46: 40% (16)<br>Occurred as early as the 4th day up to the 26th day.<br>Bilirubin >1.2: 25% (10)<br>Occurred as early as the 4th day up to the 16th day. Mostly slight increase.<br>Liver injury occurred in 17/22 critical cases 5/18 noncritical cases. |
| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations<sup>a</sup> |
|-----------------------|-------------------------|-------------------------------|----------------------------------|
| Tian, 2020<sup>36</sup> | Survival: 100% discharged | Diarrhea or vomiting: 25.8% (8/31) | AST >40: 10.8% (4) |
| Liaohe, Infectious Diseases Hospital (Liaocheng) and Liaohe People’s Hospital (Liaocheng) | Inclusion: Inpatients with COVID-19. | Present on admission | ALT >40: 5.4% (2) |
| Shandong | Age: m 44.3 ± 1.67 y | Vomiting or abdominal pain: NR | Bilirubin >1: 35.1% (13) |
| Dates: NR | Sex: 54% females | | |
| Last follow-up: NR | GI/liver comorbidities: 2.7% cirrhosis/liver cancer | | |
| | Disease severity: 13.5% mild, 81.1% moderate, 2.7% severe, 2.7% critical | | |
| Lu, 2020<sup>51</sup> | Survival: 0.4% died, 17.7% discharged. | Diarrhea: 6.4% (17) | AST M 24 (IQR, 19–33) |
| Shanghai Public Health Clinical Center | Inclusion: Inpatients with COVID-19 based on RT-PCR | Present on admission | M 24 (IQR, 19–31) in mild/moderate and M 39.5 (IQR, 29.7–53.5) in severe/critical |
| Shanghai | Age: NR | 17/243 mild/moderate and 0/22 severe/critical | ALT M 23 (IQR, 15–33) |
| Dates: ?-2/9/2020 | Sex: NR | Nausea or vomiting: 2.3% (6) | M 21 (IQR, 15–33) in mild/moderate and M 30 (24.5–34.5) in severe/critical |
| Last follow-up: 2/9/2020 | GI/liver comorbidities: 0.4% | Present on admission | Bilirubin M 0.5 (0.4–0.6) |
| | Disease severity: 91.7% mild/moderate, 8.3% severe/critically ill | Abdominal pain: NR | AST M 27 (IQR, 21.2–34.0) |
| | | | ALT M 24 (IQR, 15.3–49) |
| | | | Bilirubin 85 patients M 67.3 (IQR, 63.5–71.4) |
| | | Patients with laboratory results on admission and discharge | Patients with laboratory results on admission and discharge |
| Fu, 2020<sup>65</sup> | Survival: 100% (excluded patients who were not discharged) | Diarrhea: 13.5% (7/52) | n = 23 |
| Chengdu Public Health Clinical Medical Center (Chengdu) | Inclusion: Inpatients with COVID-19 confirmed by RT-PCR. Excluded patients who died or were not discharged. | Present on admission | AST On presentation M 27 (IQR, 23–35) |
| Sichuan | Age: M 44.5 y (IQR, 33.0–56.5 y) | Nausea: 1.9% (1/52) | After discharge M 25 (IQR, 19–39) |
| Dates: 1/1/2020-2/20/2020 | Sex: 46% females | Present on admission | ALT On presentation M 25 (IQR, 14–41) |
| Last follow-up: 2/29/2020 | GI/liver comorbidities: NR | Vomiting and abdominal pain: NR | After discharge M 31 (IQR, 15–41) |
| | Disease severity: common coronavirus pneumonia type 73.1%, severe 19.2%, critically severe 7.7% | | Bilirubin On presentation M 66 (IQR, 60–72) |
| | | | After discharge M 65 (IQR, 60–69 |
| | | | AST 11.1% (4) |
| | | | ALT 11.1% (4) |
| | | | Bilirubin 30.56% (11) |
| Fu, 2020<sup>66</sup> | Survival: 17% discharged, 6% ICU, 78% still hospitalized. | Diarrhea: % (3) | |
### Supplementary Table 1. Continued

| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations |
|-----------------------|-------------------------|--------------------------------|---------------------|
| **Jin, 2020**<sup>[2]</sup> | **n = 651** | **Diarrhea: 8.6% (56)** | AST >40: NR |
| First Affiliated Hospital of College of Medicine, Zhejiang University (Hangzhou) | Survival: 0.2% death, NR for the others | Present on admission and prior to treatment. | GI symptoms M 29.4 (IQR, 29.9–38.6) vs no GI symptoms M 24.4 (IQR, 19.0–32.0) |
| Zhejiang | Inclusion: Inpatients with COVID-19. | Defined as loose stool >3 times daily. Stool cultures were performed with negative results for all patients. *Clostridium difficile* not detected in stool and no recent antibiotic use. | ALT >50: NR |
| Dates: 1/17/2020-02/08/2020 | Age: m 45 ± 14.4 y | Median duration was 4 d (IQR, 3–6 d, range, 1–9 d). Most was self-limiting. | GI symptoms M 25.0 (IQR, 15.8–38.5) vs no GI symptoms M 21.5 (IQR, 15.0–32.8) |
| Last follow-up: 02/08/2020 | Sex: 49.2% females | Nausea/vomiting: 4.3% (28) Present on admission. | Total bilirubin |
| | GI/liver comorbidities: NR | 11 only vomiting; 10 only nausea; 3 nausea, vomiting and diarrhea; 4 nausea and vomiting. Any GI Symptom: 11.4 (74) | GI symptoms M 0.6 (IQR, 0.4–0.8) vs no GI symptoms M 0.6 (IQR, 0.4–0.8) |
| | Disease severity: Severe/critical 9.8% | Nausea, vomiting or diarrhea. 21 patients lacked respiratory symptoms of coughing and sputum production, and presented only with GI symptoms | |
| | | Severe/critical: 17/74 with GI symptoms vs 47/577 without GI symptom. In those with GI symptoms, risk factors for severe/critical disease were sputum production, increased lactate dehydrogenase and increased glucose on multivariate analysis. | |
| | | ARDS: 5/74 with GI symptoms vs 12/577 without GI symptom | |
| | | Shock: 1/74 with GI symptoms vs 1/577 without GI symptom | |
| | | Liver injury: 13/74 with GI symptoms vs 51/577 without GI symptom | |
| | | Mechanical ventilation: 5/74 with GI symptoms vs 12/577 without GI symptom ICU admission: 5/74 with GI symptoms vs 12/577 without GI symptom | |
### Study characteristics

**Qian, 2020**

- **Xiaoshan District People’s Hospital (Hangzhou), Ningbo City First Hospital (Ningbo City), Xiangshan County People’s First Hospital (Ningbo City), Affiliated Hospital of Shaoying University (Shaoxing) Ningbo Zhejiang**
- Dates: 1/20/2020-2/11/2020
- Last follow-up: 2/16/2020
- n = 91
- Survival: 0% died, 34.1% discharged, 65.9% still hospitalized.
- Inclusion: Inpatients with COVID-19 (88 based on RT-PCR and 3 based on clinical diagnosis)
- Age: M 50 y (IQR, 36.5–57 y)
- Sex: 59% females
- GI/liver comorbidities: NR
- Disease severity: 90.1% mild and 9.9% severe

**Chen, 2020**

- **Wenzhou Central Hospital (Wenzhou) and Sixth People’s Hospital of Wenzhou (Wenzhou) Zhejiang**
- Dates: 1/11/2020-2/15/2020
- Last follow-up: NR
- n = 175
- Survival: 29.7% discharge, not reported otherwise
- Inclusion: Inpatients with COVID-19 based on RT-PCR.
- Age: M 46 y (IQR, 34–54 y)
- Sex: 52.6% females
- GI/liver comorbidities: NR
- Disease severity: NR

**Kuang, 2020**

- **All Zhejiang Province Zhejiang**
- Dates: 1/1/2020-2/10/2020
- Last follow-up: NR
- n = 944
- Survival: NR
- Inclusion: All reported COVID-19 cases. Both inpatients and outpatients.
- Age: m 47.4 ± 22.9 y
- Sex: 49.6% females
- GI/liver comorbidities: NR
- Disease severity: NR

**US studies**

**Arentz, 2020**

- **Evergreen Hospital (Kirkland) Washington**
- Dates: 2/20/2020-3/5/2020
- Last follow-up: 3/17/2020
- n = 21
- Survival: 52.4% died, 9.5% out of IC, 38.1% still in ICU.
- Inclusion: Critically ill COVID-19 patients.
- Age: m 70 y (range, 43–92 y)
- Sex: 48% females
- GI/liver comorbidities: 4.8% cirrhosis, 9.5% solid organ transplant
- Disease severity: 100% critically ill

### Patient characteristics

- **Qian, 2020**
  - GI manifestations: Diarrhea: 23.1% (21)
  - Liver Manifestations: Not extracted

- **Chen, 2020**
  - GI manifestations: Diarrhea: 19.4% (34)
  - Liver Manifestations: Not extracted

- **Kuang, 2020**
  - GI manifestations: Diarrhea: 2.7% (21)
  - Liver Manifestations: NR

- **Arentz, 2020**
  - GI manifestations: Diarrhea, nausea, vomiting, and abdominal pain: NR
  - Liver Manifestations: AST m 273 (range, 14-4432) ALT m 108 (range, 11-1414) Bilirubin m 0.6 (range, 0.2-1.1)
| Study characteristics          | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations\(^a\) |
|-------------------------------|-------------------------|---------------------------------|---------------------------|
| Cholankeril, 2020\(^70\)      | n = 116                 | Diarrhea: 10.3% (12)            | AST (n = 65)             |
| Stanford University Hospitals | Survival: 0.9% died, 86.2% discharged, 4.3% still hospitalized. | Present on admission | M 35 (IQR, 22–58) |
| California                    | Inclusion: COVID-19 confirmed based on RT-PCR. | Nausea and/or vomiting: 10.3% (12) | In those with any abnormal LFT, M 64 (IQR, 24–76) |
| Dates: 3/4/2020-3/24/2020     | Age: M 50 y (IQR, 35–67 y) | Present on admission | ALT (n = 65)               |
| Last follow-up: 3/24/2020     | Sex: 46.6% females      | Abdominal pain: 8.8% (10)       | M 32 (IQR, 22–48) |
|                              | GI/liver comorbidities: 2.6% chronic liver disease | Present on admission | In those with any abnormal LFT, M 59 (IQR, 22–76) |
|                              | Disease severity: 71.6% evaluated in ED/clinic only, 20.7% admitted to the medical floor, and 7.8% admitted to ICU. | None of the patients had isolated GI symptoms or as the initial symptoms. | Total bilirubin (n = 65) |
|                              |                         | 31.9% reported GI symptoms. Median duration of GI symptoms was 1 day (IQR, 0–4). | M 0.4 (IQR, 0.3–0.7) |
|                              |                         |                                | In those with any abnormal LFT, M 0.5 (IQR, 0.3–0.7) |
|                              |                         |                                | 26 patients developed liver enzyme elevation. 22 of them had normal baseline liver enzymes. |

| Nobel, 2020\(^37\)           | n = 278                 | Diarrhea: 20.1% (56)            | AST: NR                   |
| New York–Presbyterian Hospital/Columbia University Irving Medical Center | Survival: 3.2% died, | Present on admission | ALT: NR                   |
| New York                     | Inclusion: Patients tested for COVID-19 at clinic or emergency department for respiratory symptoms with intent to hospitalize or the same symptoms in essential personnel. | 42/207 admitted to hospital, 11/44 admitted to ICU, 0/9 died. | Bilirubin: NR          |
| Dates: 3/10/2020-3/21/2020   | Excluded patients with insufficient data (42). Charts randomly selected. | Vomiting/vomiting: 22.7% (63) |                           |
| Last follow-up: 18 days after testing | Age: 11% aged 18–30 y, 25% aged 31–50 y, 37% aged 51–70 y, and 27% aged >70 y | Present on admission |                           |
|                              | Sex: 48% females        | Abdominal pain: NR |                           |
|                              | GI/liver comorbidities: NR | 51/207 admitted to hospital, 8/44 admitted to ICU, 0/9 died. |                           |
|                              | Disease severity: 74.5% admitted to hospital, 15.8% admitted to ICU, 3.2% died. | Abdominal pain: NR |                           |
|                              |                         | 35% had GI symptoms. Patients with GI symptoms were more likely to have illness duration of ≥1 week (33%) compared to patients without symptoms (22%). |                           |
|                              |                         | Presence of GI symptoms (diarrhea or nausea/vomiting) was associated with a 70% increased risk of testing positive (adjusted odds ratio 1.7; 95% CI, 1.1–2.5) |                           |
| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations<sup>a</sup> |
|-----------------------|-------------------------|--------------------------------|---------------------------------|
| Hajifathalian, 2020<sup>53</sup> NewYork-Presbyterian Hospital/ Weill Cornell Medical Center New York | n = 1059 (768 inpatients and 291 outpatients) Survival: 9.1% died Inclusion: Adults with COVID-19, inpatients and outpatients. Age: m 61 ± 18 y Sex: 42.3% females GI/liver comorbidities: 1.6% IBD, 3.0% chronic liver disease, 2.4% solid organ transplant. Disease severity: NR | Diarrhea: 22.1% (234) Present on admission Inpatients 24.3% (187/768) and outpatients 16.1% (47/291). Vomiting: 8.3% (91) Present on admission Inpatients 8.7% (67/768) and outpatients 8.2% (24/291). Nausea: 15.3% (168) Present on admission Inpatients 16.0% (123/768) and outpatients 15.5% (45/291). Abdominal pain: 6.6% (72) Present on admission Inpatients 7.3% (56/768) and outpatients 5.5% (16/291). | AST ≥40: 56% (n = 844) m 60 ± 79 ALT ≥40: 39% (n = 844) m 50 ± 65 Bilirubin >1.2: 11% (n = 844) m 0.7 ± 0.6 Presence of liver injury at presentation was associated with higher risk of admission on multivariate analysis. |
| Kujawski, 2020<sup>57</sup> Center of Disease Control California, Illinois, Arizona, Massachusetts, Washington, Wisconsin | n = 12 Survival: 0% died, 8.3% hospitalized, 41.7% home isolation, 50% recovered. Inclusion: Patients under investigation who tested positive for COVID-19. Age: M 53 y (range, 21–68 y) Sex: 33.3% females GI/liver comorbidities: 8.3% HBV and 8.3% fatty liver disease Disease severity: 5 outpatients and 7 inpatients. | Diarrhea: 33.3% (4) 8.3% (1) present on admission 3 while on remdesivir (1 of them had *Giardia* and *C difficile*). 1 patient had symptoms for 1 day then developed fever and cough. Nausea: 25% (3) 8.3% (1) present on admission Abdominal pain: 16.7% (2) Stool PCR positive in 70% (7/10) patients | AST: 58.3% (7) M 129 (IQR, 46–190) ALT 58.3% (7) M 136 (IQR, 66–389) Bilirubin NR |
| Rubin, 2020<sup>63</sup> Stanford University School of Medicine California | n = 54 Survival: NR. Inclusion: COVID-19 patients, not clear otherwise. Age: M 53.5 y (IQR, 32–75 y, range, 20–91 y) Sex: 46.3% females GI/liver comorbidities: 1.8% HBV Disease severity: 33.3% inpatients and 66.7% outpatients | Diarrhea, nausea, vomiting, and abdominal pain: NR | AST Females m 73.4 ± 61.8 (9) and males m 45.1 ± 19.5 (14) ALT Females m 69.6 ± 65.2 (9) and males m 43.9 ± 25.8 (13) Bilirubin NR |
| Other countries COVID-19 National Emergency Response Center, 2020<sup>56</sup> South Korea | n = 28 Survival: NR Inclusion: Inpatients or outpatient with COVID-19 Age: m 42.6 y (range, 20–73 y) Sex: 46.1% females GI/liver comorbidities: NR Disease severity: NR | Diarrhea: 7% (2) Present on admission 1 started 2 d after fevers and chills and 1 started 2 d after muscle aches Abdominal pain: 4% (1) Present on admission Stomachache 2 d after muscle ache Vomiting and nausea: NR | NR |
| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations |
|------------------------|-------------------------|---------------------------------|---------------------|
| Young, 2020<sup>a</sup> Singapore Dates: 1/23/2020-2/3/2020 Last follow-up: 2/25/2020 | n = 18 Survival: NR Inclusion: Inpatients COVID-19 based on RT-PCR Age: M 47 y (range, 31–73 y) Sex: 50% females GI/liver comorbidities: NR Disease severity: NR (12 patients uncomplicated (67%) 6 required oxygen (33%)) | Diarrhea: 17% (3) Present on admission None of these patients required supplemental oxygen Vomiting, nausea, and abdominal pain: NR Virus detected by PCR in stool in 4/8 (50%) and in whole blood 1/12 (8%) 4 of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results | NR |
| Sun, 2020<sup>b</sup> The National Centre for Infectious Diseases Singapore Dates: 1/26/2020-2/16/2020 Last follow-up: NR | n = 54 Survival: NR Inclusion: Patients referred for testing for COVID-19 Age: M 42 y (IQR, 34–54 y) Sex: 46% females GI/liver comorbidities: 0 liver disease Disease severity: NR | GI symptoms: 37% (20/54) General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) | AST, ALT, and bilirubin NR |
| Pung, 2020<sup>c</sup> Singapore Dates: 1/27/2020-2/15/2020 Last follow-up: NR | n = 17 Survival: 0% died Inclusion: Inpatients COVID-19 based on PCR Age: M 40 y (IQR, 36–51 y) Sex: 59% females GI/liver comorbidities: NR Disease severity: NR | Diarrhea: 23.5% (4) Nausea/Vomiting: 5.9% (1) Abdominal pain: NR | AST, ALT, and bilirubin: NR |
| Tabata, 2020<sup>d</sup> Diamond Princess Cruise Japan Dates: 2/11/2020-2/25/2020 Last follow-up: NR | n = 104 Survival: 0% died, NR otherwise Inclusion: Laboratory confirmed patients with COVID-19 on Diamond Princess Cruise ship Age: M 68 y (IQR, 46.8–75 y; range, 25–93 y) Sex: 54.8% females GI/liver comorbidities: NR Disease severity: 31.7% asymptomatic, 41.3% mild, 26.9% severe. | Diarrhea: 9.6% (8) Present on admission 2 additional patients develop diarrhea during the hospitalization | AST >38: 17.3% (18) 9/76 (11.8%) nonsevere and 9/28 (32.1%) severe ALT >45: 16.3% (17) 10/76 (13.2%) nonsevere and 7/28 (25%) severe Bilirubin: NR |
| Study characteristics                  | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations |
|----------------------------------------|-------------------------|---------------------------------|----------------------|
| Kluytmans, 2020\(^{19}\)              | n = 86                  | Diarrhea: 18.6% (16)            | AST, ALT, and bilirubin: NR |
| Breda and Tiburg, The Netherlands      | Survival: 0 deaths, 2 required short hospitalization. | Interviewed within 7 d of onset of symptoms: 5/31, interviewed after 7 d of onset of symptoms: 11/55 | AST, ALT, and bilirubin: NR |
| Dates: 3/7/2020-3/12/2020              | Inclusion: Health care workers with fever or mild respiratory symptoms more than 10 d with subsequent positive tests. Outpatients. | Decreased appetite or nausea: 17.4% (15) interviewed within 7 d of onset of symptoms: 1/31, interviewed after 7 d of onset of symptoms: 14/55 | AST, ALT, and bilirubin: NR |
| Last follow-up: NR                     | Age: M 49 y (range, 22-66 y) | Abdominal pain: 5.8% (6) interviewed within 7 d of onset of symptoms: 1/31, interviewed after 7 d of onset of symptoms: 3/55 | AST, ALT, and bilirubin: NR |
|                                        | Sex: 4.6% females       |                                 | AST, ALT, and bilirubin: NR |
|                                        | GI/liver comorbidities: NR |                                 | AST, ALT, and bilirubin: NR |
|                                        | Disease severity: 2 hospitalized, 19 recovered |                                 | AST, ALT, and bilirubin: NR |
| Wolfel, 2020\(^{32}\)                 | n = 9                   | Diarrhea: 22% (2)               | Ast, ALT, and bilirubin: NR |
| Munich, Germany                        | Survival: NR            | Present on admission            | Ast, ALT, and bilirubin: NR |
| Dates: 1/23/2020-?                    | Inclusion: lab confirmed SARS-Co-V-2 in upper respiratory specimens | Diarrhea was never the only symptom | Ast, ALT, and bilirubin: NR |
| Last follow-up: NR                     | Age: NR                 | PCR was positive for up to 11 d; Authors were not able to isolate infectious virus, despite high stool RNA viral loads. | Ast, ALT, and bilirubin: NR |
|                                        | Sex: NR                 | Vomiting, nausea and abdominal pain: NR | Ast, ALT, and bilirubin: NR |
|                                        | GI/liver comorbidities: NR |                                 | Ast, ALT, and bilirubin: NR |
|                                        | Disease severity: NR    |                                 | Ast, ALT, and bilirubin: NR |
| Dreher, 2020\(^{68}\)                 | n = 50                  | Diarrhea: 16% (8/50)            | Ast, ALT, and bilirubin: NR |
| Aachen, Germany                        | Survival: 14% died, 16% discharged, 70% still hospitalized | Present on admission 6/24 ARDS, 2/26 non-ARDS | Ast, ALT, and bilirubin: NR |
| Dates: 2/1/2020-3/1/2020               | Inclusion: Inpatients with laboratory confirmed COVID-19 | Nausea: 1/50 | Ast, ALT, and bilirubin: NR |
| Last follow-up: NR                     | Age: median 65 y (IQR, 58–76 y) | Present on admission 0/24 ARDS, 1/26 nonARDS | Ast, ALT, and bilirubin: NR |
|                                        | Sex: 34% females        | Vomiting: 2/50 | Ast, ALT, and bilirubin: NR |
|                                        | GI/liver comorbidities: chronic liver failure 8%, chronic hepatitis 10% | Present on admission 1/24 ARDS, 1/26 non-ARDS | Ast, ALT, and bilirubin: NR |
|                                        | Disease severity: 48% ARDS, 52% non-ARDS | Stool PCR done in 15 patients and found positive in 2 patients with ARDS | Ast, ALT, and bilirubin: NR |
| Gritti, 2020\(^{54}\)                 | n = 21                  | Diarrhea: 23.8% (5)             | Ast, ALT, and bilirubin: NR |
| Papa Giovanni XXIII Hospital           | Survival: 4.7% died, NR for the others | Present on admission | Ast, ALT, and bilirubin: NR |
| Bergamo, Italy                         | Inclusion: Inpatients with confirmed COVID-19 who received | Nausea or vomiting, or abdominal pain: NR | Ast, ALT, and bilirubin: NR |
| Dates: 3/11/2020-3/24/2020             | Age: m 64 y (range, 48–75 y) | | Ast, ALT, and bilirubin: NR |
| Last follow-up: NR                     | Sex: 14% females | | Ast, ALT, and bilirubin: NR |
|                                        | GI/liver comorbidities: NR | | Ast, ALT, and bilirubin: NR |
|                                        | Disease severity: NR | | Ast, ALT, and bilirubin: NR |
### Supplementary Table 1. Continued

| Study characteristics | Patient characteristics | Gastrointestinal manifestations | Liver Manifestations<sup>a</sup> |
|-----------------------|-------------------------|---------------------------------|----------------------------------|
| **Spiteri, 2020<sup>10</sup>**<br>Germany, Finland, Italy, Russia, Spain, France, Sweden, and Belgium<br>Dates: 1/24/2020-2/21/2020<br>Last follow-up: 2/21/2020 | n = 38<br>Survival: 2.6% died, 11.4% still hospitalized<br>Inclusion: Inpatients (n = 35) and outpatients (N=2) with COVID-19 confirmed based on RT-PCR | Diarrhea: 3.2% (1/31)<br>Present on diagnosis | AST, ALT, and bilirubin: NR |
| **COVID-19 National Incident Room Surveillance Team, 2020<sup>37</sup>**<br>Australia<br>Dates: National data until 3/14/2020<br>Last follow-up: 3/14/2020 | n = 295<br>Survival: 1.0% died<br>Inclusion: All individuals with COVID-19 (both outpatients and inpatients) | Diarrhea: 16.3% (48)<br>Nausea/vomiting: 11.5% (34)<br>Abdominal pain: 2.0% (6) | No laboratory data reported |

ARDS, acute respiratory distress syndrome; CT, computed tomography; HBV, hepatitis B virus; ICU, intensive care unit; IQR, interquartile range; M, median; m, mean; ±, standard deviation; NR, not reported.

<sup>a</sup>AST and ALT are reported as units per liter while bilirubin is reported as milligrams per deciliter.
### Supplementary Table 2. Direct Evidence of Proposed COVID-19 Therapies

| Medication class | Medication  | Source* | Study Design | GI adverse effects |
|------------------|-------------|---------|--------------|--------------------|
| Antiviral        | Favipiravir | Cai, 2020<sup>109</sup> | Open-label control study (favipiravir and lopinavir/ritonavir) for COVID-19 | NR | NR | 2/35 (5.7%) had diarrhea | 1/35 (2.9%) |
|                  |             | Chen, 2020<sup>12</sup> | Open-label RCT for favipiravir vs arbidol (n = 120) in COVID-19 | “Digestive tract reactions” 16/116 (13.79%) | NR | 9/116 (7.76%) |
| Lopinavir/ritonavir | Cao, 2020<sup>88</sup> | RCT in severe COVID-19 (n = 199) | 10/95 with nausea + 6/96 vomiting (reported separately) vs 0/99 with nausea and 0/99 with vomiting in control | 4/95 in treatment group vs 2/99 in control group | 4/95 in treatment group vs 0/99 in control group | 6/95 in treatment group vs. 5/99 in control group | Elevated AST: 4/95 in treatment vs. 9/99 in control group; Elevated ALT: 2/95 in treatment vs 5/99 in control group |
| Remdesivir       | Holshue, 2020<sup>103</sup> | Case report (first COVID in United States): remdesivir given day 7; no adverse events reported | Not reported in systematic review or primary studies |
| Antimalarial     | Chloroquine | Cortegiani, 2020<sup>104</sup> | Systematic review on efficacy and safety in COVID-19 | Not reported in systematic review or primary studies |
| Hydroxychloroquine |           |         |              |                     |

NR, not reported.

*Sources include existing systematic reviews where possible. If not available, primary sources are listed.
### Supplementary Table 3. Indirect Evidence of Proposed COVID-19 Therapies

| Medication class | Medication | Source\textsuperscript{a} | Indirect | Nausea/vomiting | Abdominal pain | Diarrhea | Jaundice | Hepatotoxicity | Other |
|------------------|------------|---------------------------|----------|-----------------|----------------|----------|----------|----------------|-------|
| Antiviral        | Lopinavir/ritonavir | FDA/manufacturer’s label\textsuperscript{10} | HIV      | Nausea (5%–16%); vomiting (children 21%; adults 2%–7%); Reported 1%–11% | 7%–28%; greater with once-daily dosing | —        | Increased serum ALT: 1%–11%; hepatitis including AST/ALT/ GGT elevations: 4%; hyperbilirubinemia (children 3%; adults 1%) | Dysgeusia (children 22%; adults <2%); hyperamylasemia (3%–8%), dyspepsia (<6%), increased lipase (3%–5%), flatulence (1–4%), gastroenteritis (3%) |
|                  |            | NIH Liver Tox\textsuperscript{11} | HIV      |                  |                |          |          | Range from mild to ALF. Recovery takes 1–2 mo. Do not re-challenge with medication. Monitor for exacerbation of HBV/HCV |
|                  |            | Momattin,\textsuperscript{105} 2019 | MERS     | Prevalence of GI AEs not reported in this SR | |          |          | SARS: 2 retrospective cohort studies (combined with steroids); MERS: 1 RCT combined with IFN, 1 retrospective cohort combined with IFN/ribavirin, and 2 case reports also combined with IFN/ribavirin |
|                  | Remdesivir | Al-Tawfiq,\textsuperscript{107} 2020 | MERS | AEs not reported in this SR (can check primary studies) | |          |          | |

\textsuperscript{a} Source: NIH Liver Tox (2019).
## Supplementary Table 3. Continued

| Medication class | Medication       | Sourcea | Indirect | Nausea/vomiting | Abdominal pain | Diarrhea | Jaundice | Hepatotoxicity | Other |
|------------------|------------------|---------|----------|-----------------|----------------|----------|----------|----------------|-------|
| Antimalarial     | Chloroquine      | FDA/manufacturer’s label/NIH Liver Tox111,112 | Malaria | Reported; frequency not defined | Abdominal cramps reported; frequency not defined | Reported; frequency not defined | Rarely linked to aminotransferase elevations or clinically apparent liver injury. In patients with AIP or PCT, it can trigger an attack with fever and serum aminotransferase elevations, sometimes resulting in jaundice. | Minor metabolism by liver (~30%); mostly excreted in urine | Likelihood score: D (possible rare cause of clinically apparent liver injury) |
|                  | Hydroxychloroquine | FDA / Manufacturer’s label | Malaria/ SLE | Reported; frequency not defined | Reported; frequency not defined | Reported; frequency not defined | Same as chloroquine above; can be exchanged with chloroquine as most reactions are hypersensitivity and no known cross reactivity to hepatic injury. | | Likelihood score: D (possible rare cause of clinically apparent liver injury) |

AE, adverse event; AIP, acute intermittent porphyria; ALF, acute liver failure; GGT, gamma-glutamyl transferase; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; NIH, National Institutes of Health; PCT, porphyria cutanea tarda; SLE, systemic lupus erythematosus; SR, systematic review.

Sources include existing systematic reviews where possible. If not available, primary sources are listed.